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ABSTRACT 
Breast cancer is the most common cancer in women. Although the incidence of breast cancer 
has increased over time, so too has patient survival. Given these trends, the prevalence of breast 
cancer has steadily increased in recent decades, exposing these women to other associated 
diseases which can influence carcinogenesis, prognosis, and treatment. This thesis uses 
Swedish register data, combined with data from the Libro-1 and Karolinska Mammography 
Project for Risk Prediction of Breast Cancer (KARMA) cohorts, to study other diseases 
associated with breast cancer in women. Specifically, this thesis investigates how diseases in 
early adulthood influence the risk of breast cancer, and how overall health is affected by breast 
cancer treatment.  
In Study I, the risk of breast cancer in women with and without preeclampsia was studied using 
data from the Swedish Medical Birth Register and KARMA cohort. Women diagnosed with 
preeclampsia had a decreased risk of breast cancer and lower mammographic density. In 
addition, sisters of breast cancer patients and women with a high genetic predisposition to 
breast cancer had a lower risk of preeclampsia. This suggests that inherited factors may 
contribute to the inverse association between preeclampsia and breast cancer.  
In Study II and Study III, the risk of mental disorders and psoriasis were compared between a 
Swedish nationwide cohort of breast cancer patients and the general population. Women with 
invasive breast cancer had an increased risk of depression, anxiety, stress-related disorders, and 
psoriasis. This increased risk was greatest shortly after cancer diagnosis and remained over the 
subsequent five years. Patients with in-situ breast cancer only experienced an increased risk of 
stress-related disorders during the first six months after cancer diagnosis. With regard to risk 
predictors, the Libro-1 cohort of Stockholm-Gotland breast cancer patients showed that 
younger age at diagnosis, higher tumor grade, lymph node positive tumors, comorbidity, and 
chemotherapy were independently associated with an increased risk of depression and anxiety. 
The effect of tumor grade and chemotherapy was mainly limited to the first two years after 
diagnosis, while comorbidity contributed to long term risk. Younger age at diagnosis was the 
only risk factor identified for stress-related disorders; while for psoriasis, radiotherapy and 
mastectomy were associated with increased disease risk. Aside from these treatment-specific 
predictors, genetic predisposition, obesity and smoking were also risk factors for psoriasis in 
breast cancer patients.  
Study IV used a matched cohort design to describe a wide spectrum of diseases after breast 
cancer diagnosis. In a Swedish nationwide breast cancer cohort, breast cancer patients had an 
increased risk of infection and several non-communicable diseases, compared to matched 
healthy individuals. Diseases with the highest hazard ratios - lymphedema, radiodermatitis, and 
neutropenia - correspond to the side effects of surgery, radiotherapy, and chemotherapy. 
Despite an increased incidence of many diseases, increased mortality risk among breast cancer 
patients was only due to other solid cancers. A higher risk of other solid cancers could be 
predicted by menopausal disorders, indicating the need for gynecological surveillance of breast 
cancer patients.  
In conclusion, our results suggest that inherited factors contribute to an inverse association 
between preeclampsia and breast cancer, given that the inverse association was also found 
between preeclampsia and women with a high genetic predisposition to breast cancer. This 
thesis identifies an increased risk of several diseases after breast cancer diagnosis, including 
menopausal disorders, mental disorders, and psoriasis. Such diseases are related to cancer 
treatment, and suggest that a multidisciplinary perspective on post-cancer care is required for 
breast cancer patients. 
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1 INTRODUCTION 
 
Breast cancer is the most prevalent cancer among women worldwide, and the number of breast 
cancer patients is increasing in both developed and developing countries [1]. Several factors 
have contributed to this increasing trend, such as lifestyle transitions, the coverage of screening 
programs, and improvements in treatment, which led to a large number of women living with 
a history of breast cancer disease. This prolonged survival time after breast cancer diagnosis 
also makes it possible to investigate the occurrence of other diseases among breast cancer 
patients. These diseases might not only influence treatment decisions and patient prognosis but 
also quality of life and social welfare. In Sweden, the well-established health care registers that 
cover the entire nation provide an opportunity to study these diseases, and the results we 
observe in Sweden may shed light on clinical practice in other countries. 
There are several reasons for other diseases to be associated with breast cancer. The pleiotropic 
effect of genetic variants and certain unhealthy lifestyle factors may affect the risk of many 
diseases, including breast cancer. In this thesis, we wanted to investigate how diseases in early 
adulthood influence a woman’s risk of breast cancer and whether genetic variants contribute to 
the association. Considering the roles of hormones in breast tumor carcinogenesis, several 
hormone-related diseases have been studied to test their association with breast cancer risk, 
including preeclampsia.  
Treatments for breast cancer might be toxic for other organ systems and increase the risk of 
other diseases. A diagnosis of cancer per se is a stressful life event, which can impair patient 
mental health. In this thesis, we also tried to reveal the effect of cancer diagnosis and treatment 
on the risk of other diseases after breast cancer diagnosis, with a focus on mental disorders and 
psoriasis, considering their impact on patient quality of life and welfare. 
In addition to diseases with a known association with breast cancer, many other diseases have 
not been studied in these patients. Therefore, we screened across a wide spectrum of diseases 
among breast cancer patients to discover unknown associations. We also attempted to link the 
sequential pattern of disease incidence to the mortality of patients. These efforts may help to 
identify key diagnostic indicators to aid in early detection and treatment of life-threatening 
outcomes later in life. 
 
 
  3 
2 BACKGROUND 
2.1 EPIDEMIOLOGY OF BREAST CANCER 
Breast cancer is one of the most common cancers diagnosed worldwide. It has been reported 
that one in ten women will be diagnosed with breast cancer in their lifetime in developed 
countries. In 2016, approximately 1.7 million women are diagnosed with breast cancer, which 
represents 22% of all female cancers [1]. Generally, breast cancer is a female cancer, and less 
than 1% of patients are male [2]. The annual incidence of new cases is higher in more developed 
regions than in less developed regions of the world (1.06 and 0.64 million cases in 2016, 
respectively), as well as the incidence rate of breast cancer (88.1 per 100,000 person-years 
compared to 18.8 per 100,000 person-years). Geographically, women from North America and 
Western European countries suffer from a higher incidence of breast cancer  [1] (Figure 2.1). 
 
 
Figure 2.1 Geographic view of breast cancer incidence and mortality in 2016. 
Data obtained from a publication of Global Burden of Disease Cancer Collaboration [1]. 
Breast cancer ranks as the first cause of death for women among all cancer types and the fifth 
cause of death among all diseases worldwide [3]. Different from the large disparity in breast 
cancer incidence throughout the world, the mortality rate of breast cancer is not quite different 
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in more developed and less developed regions (15.5 and 7.4 per 100,000 person-years, 
respectively), possibly because of better screening and treatment in more developed regions. 
In Sweden, breast cancer accounts for 29.2% of all female cancers and 13.0% of cancer 
mortality, with an annual incidence of 7,558 and mortality of 1,391 patients in 2016 [4]. The 
incidence rate of breast cancer has nearly doubled from 72.5 per 100,000 person-years in 1965 
to 150.5 per 100,000 person-years in 2015 [5]. Despite the increasing incidence of breast cancer 
over time, more patients currently survive the disease. Thanks to the nationwide 
mammographic screening program and improved treatments, the five-year survival rate of 
Swedish breast cancer patients has increased from 82% in 1990-1994 to 92% in 2016 [4, 5]. 
Due to these trends in incidence and survival, the number of prevalent breast cancer cases has 
increased steadily over the past decades. In 2016, there are approximately 108,000 breast 
cancer patients in Sweden. 
 
Figure 2.2 Incidence and mortality rates of breast cancer in Sweden 
Data obtained from NORDCAN [5]. 
2.2 RISK FACTORS FOR BREAST CANCER 
Breast cancer is a hormone-related cancer with a heritability of 31%. Common environmental 
and individual environmental factors explain the other 16% and 53% of the disease liability 
[6]. An overview of the major risk factors for breast cancer is presented in Figure 2.3, showing 
genetic, hormone and other lifestyle factors. 
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Figure 2.3 Relative risk of breast cancer according to gene, hormone and lifestyle factors 
2.2.1 Family history and genetic factors 
An increased risk of breast cancer has been shown in women with a family history of breast 
cancer. Women with any affected first-degree relatives have a twice increased risk of breast 
cancer, and the affected second-degree relatives are associated with a 50% increased risk [7]. 
Compared to women with no affected relatives, the risk of breast cancer is increased by 80%, 
twice and three times in women with one, two and more than two affected relatives, 
respectively [8].  
The strong effect of family history is partly explained by inherited genetic mutations, with the 
famous BRCA1 and BRCA2 genes accounting for 16% of the familial risk and other genes, 
such as PTEN, P53, STK11 and CDH1, accounting for approximately 5% [9]. The rare 
moderate-penetrance breast cancer susceptibility genes, including CHEK2, ATM, BRIP1 and 
PALB2, contribute to a much lower proportion of familial risk (approximately 2.3%). Thus, 
the majority of the family history effect is hypothesized to be originated from common 
polygenic variance. Figure 2.4 illustrates the liability of breast cancer by these genetic variants. 
With the development of high throughput genotyping technology, various Genome-Wide 
Association Studies (GWAS) have been performed to harvest new Single Nucleotide 
Polymorphisms (SNPs) for breast cancer. An SNP is a single allele alteration in the DNA chain 
with a frequency of more than 1% in the population and therefore is viewed as a common 
genetic variance. Current efforts by a consortium of researchers have discovered 172 breast 
cancer-associated loci, explaining approximately 18% of the familial risk of breast cancer [10]. 
The significant SNPs can be summed up to a polygenic risk score (PRS) for breast cancer risk 
prediction. Women with the highest 1.5% PRS experience a three-fold increased risk of breast 
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cancer compared with the remaining population [11]. Adding the PRS into the common breast 
cancer prediction tools also increases the precision of prediction [12].  
 
Figure 2.4 Breast cancer disease liability by gene and environment factors 
2.2.2 Hormone-related factors 
Breast tissue is sensitive to hormones, especially estrogen and progesterone. Approximately 
75% of breast tumors express estrogen receptor alpha [13]. In postmenopausal women, a higher 
level of total circulating estrogen is strongly associated with an increased risk of breast cancer 
[14]. An excess serum level of androgen also contributes to higher breast cancer risk in these 
women [15], probably through aromatase activity in fat tissues. For premenopausal women, 
the estrogen level fluctuates across the menstrual cycle and thus is difficult to compare. 
However, studies still suggest a positive association between circulating estrogen level and 
breast cancer risk in premenopausal women [16].  
The duration of exposure to estrogen is also important, because the lifelong exposure to 
estrogen depends on both the level of estrogen and duration of exposure. Reproductive factors 
indicating a longer period of ovarian activity, such as early menarche, late menopause and more 
menstrual cycles, increase the risk of breast cancer [17]. However, breastfeeding, early age at 
first pregnancy and multiple pregnancies may influence the differentiation of mammary gland 
cells and consequently protect women from breast cancer [18]. In addition, pregnancy 
characteristics and related diseases, including placenta weight and preeclampsia also affect 
breast cancer risk in later life [19, 20]. 
In addition to endogenous hormones, exogenous hormones also increase breast cancer risk. 
Hormone replacement therapy has been used to maintain the serum estrogen level and relieve 
menopausal syndromes (hot flushes, osteoporosis, psychological change, etc.) [21]. Current 
and recent users of hormone replacement therapy have an approximately 14% increased risk 
of breast cancer [22], which is mainly due to the continuous combined estrogen plus progestin 
therapy [23]. Similar to hormone replacement therapy, oral contraceptive users have an 
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increased breast cancer risk; however, this increased risk diminishes beyond 10 years after drug 
cessation [24].  
2.2.3 Mammographic density 
Mammographic density refers to the sum of pixels in the mammogram, which corresponds to 
dense breast tissues. The pixels are generated by X-rays that permeate different types of breast 
tissues differently, with dark areas referring to fat tissues and white pixels referring to epithelial 
and stromal tissues [25].  Mammographic density is often analyzed by comparison with the 
entire breast area, resulting in a percent density. Mammograms showing the mediolateral 
oblique view were usually measured, and in our group, the full automated software STRATUS 
was used to measure area-based mammographic density (absolute dense area and percent 
density). The STRATUS software can measure both raw and processed mammogram images 
regardless of the vendor of the mammography machine and allows comparison of 
mammographic density at the population level [26]. An illustration of the mammograms is 
shown in Figure 2.5. A higher percent density is a strong risk factor for breast cancer [27], and 
inclusion of mammographic density in the breast cancer risk prediction models increases the 
discriminatory accuracy [28]. 
 
Figure 2.5 Illustration of mammograms measured by our group [29]. 
Left: mammogram with low percent density; right: mammogram with high percent density. 
2.2.4 Other lifestyle factors  
Similar to other cancers, lifestyle factors play an important role in breast cancer development. 
Cigarette smoking has been shown to increase breast cancer risk by 20%, especially for women 
who initiate smoking before their first delivery [30]. Likewise, alcohol consumption is 
positively associated with the risk of both ER-positive and ER-negative breast cancer [31], and 
even a moderate dosage can increase the risk [32]. Body mass index (BMI), as an indicator of 
body fat distribution, slightly decreases the risk of breast cancer in premenopausal women but 
elevates breast cancer risk in postmenopausal women [33, 34]. This disparity is probably due 
to a change in the main source of endogenous estrogen, from the ovary to adipose cells after 
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menopause. Independent of BMI, women who exert a higher level of physical activity 
experience a reduction in breast cancer risk compared with less active individuals [35]. 
2.3 DIAGNOSIS OF BREAST CANCER 
2.3.1 Current approaches to diagnosis 
In the 1990s, Sweden started the nationwide breast cancer screening program, and according 
to the detection mode, breast cancer can be divided into screening-detected cancers and interval 
cancers. If the radiologists find a suspicious image in the screening mammogram, the patients 
will be recalled for an additional mammogram or ultrasound, as well as a fine needle aspiration, 
to confirm whether there is a tumor. Patients diagnosed with interval cancers typically have 
some symptoms in the breast. 
The most common symptom of breast cancer is a lump in the breast. Other possible symptoms 
include redness of the breast skin, clear or bloody fluid from the nipple, and dimpled or 
puckered breast skin (orange-like skin). In Sweden, women with these suspicious symptoms 
are referred to a standardized care process and first tested using the three major diagnostic 
approaches for breast cancer: clinical examination, imaging and biopsy (Figure 2.6) [36]. 
 
Figure 2.6 Standardized diagnostic care for breast cancer in Sweden 
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The clinical examination usually includes a review of family history, menstrual status, previous 
breast surgery, endocrine treatment and previous symptoms. The clinician should also perform 
a physical examination by palpation of both the breast and regional lymph nodes and inspection 
of the breast and overlying skin. 
Mammography is the primary imaging technique for breast cancer diagnosis. However, if the 
woman is pregnant, breastfeeding or younger than 30 years old, ultrasound is the first choice. 
For women with dense breast tissue or a family history of breast cancer, MRI may also be 
offered due to its greater sensitivity. In a mammogram, fat tissues absorb fewer X-rays and 
appear as dark areas, while fibro-glandular tissues and tumors are dense areas with bright pixels 
[25]. Mammography is used not only in clinical diagnosis of breast cancer but also in screening 
programs in Sweden due to its low cost and high efficiency.  
Although clinical examination and imaging help in diagnosing a breast tumor, cytology and 
tissue biopsy are the definitive approaches for breast cancer diagnosis. For preoperative tissue 
tests, focal point fine needle aspiration is generally sufficient if the patient is primarily operable 
and the clinical and diagnostic findings are clear. However, it is not possible to determine the 
invasiveness of a tumor by cytology, and a core needle tissue biopsy is therefore needed, which 
can also provide a better measurement of the tumor characteristics (will be described in 2.3.2). 
In a biopsy test, if cancer cells are proliferating within the basal epithelial membrane, the tumor 
is usually called an in situ cancer. However, cancer growing beyond the epithelial membrane 
and invading into the stromal cells is called invasive cancer. At the time of diagnosis, in situ 
cancer accounts for approximately 10% of all the breast cancers diagnosed in Sweden and is 
usually associated with better survival [37, 38].  
2.3.2 Tumor characteristics 
At the time of breast cancer diagnosis, several tumor characteristics are measured to investigate 
the aggressiveness of the tumor, including tumor size, lymph node involvement, hormone 
receptors, and histological grade. These tumor characteristics are usually measured by the 
pathologist using several techniques, such as immunohistochemistry and in situ hybridization. 
Tumor size, lymph node and distant metastasis 
Tumor size is a traditional measurement for breast cancer and a fundamental characteristic for 
predicting clinical outcomes after cancer [39]. However, the correlation between tumor size 
and breast cancer survival seems to only be significant in luminal (ER+/HER-2−) breast 
cancers and not in other molecular subtypes (will be introduced later), suggesting the limitation 
of tumor size as a prognostic indicator and the unpredictability of a receptor-negative cancer 
[40]. 
Axillary lymph node metastasis is the most important prognostic indicator for primary breast 
cancer, especially for patients with four or more involved lymph nodes [41]. In current clinical 
practice, a sentinel-node biopsy is performed to detect whether metastasis to the lymph node 
has occurred [42]. The sentinel node is identified with a radioactive isotope and a blue dye 
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injected into the tumor. Lymph node-positive patients usually receive a complete axillary 
dissection along with chemotherapy. 
Distant metastasis is an indicator of breast cancer with a worse prognosis because the tumor 
cells are already disseminated to other sites in the body. Approximately 5-10% of breast 
cancers are metastatic at diagnosis, and only 20% of these patients will survive for more than 
5 years [43]. Because the majority of metastatic breast cancer patients are incurable, the 
primary strategy for them is palliative care, with the aim of improving their quality of life and 
extending their survival time. 
A summation of these three tumor characteristics is the TNM classification system, which was 
developed in the 1970s and was recently updated to the 8th version in 2017 [44]. The details 
of TNM classification are summarized in Table 2.1. According to the TNM classification, 
tumor grade, hormone receptor status and gene panels, breast cancer can be categorized into 
four stages. When breast cancer is diagnosed, approximately 60% of the patients have stage 0-
I cancer, 30% have stage II-III cancer and less than 10% have stage IV cancer. Stage 0-III 
breast cancer patients usually have an approximately 90% five-year survival rate, while for 
stage IV cancer patients, the five-year survival rate is approximately 20-30% [45]. 
Table 2.1 American Joint Committee on Cancer Definition of TNM 
Category            Criteria 
Tumor size (T) 
Tx Tumor size can not be assessed 
T0 No evidence of tumor 
Tis Carcinoma in situ 
T1 Tumor size ≤ 20 mm in the greatest dimension 
T2 Tumor size >20 mm but ≤50 mm in the greatest dimension 
T3 Tumor size >50 mm in the greatest dimension 
T4 Tumor of any size with invasion into the chest wall or the skin  
Regional lymph nodes (N) 
Nx Regional lymph nodes can not be assessed  
N0 No metastasis to lymph node 
N1 Metastases to ipsilateral level I and II axillary lymph node(s), and are still movable 
N2 Metastases in ipsilateral level I and II axillary lymph nodes, but are clinically fixed or matted or 
Metastases in ipsilateral internal mammary lymph nodes without evidence of axillary lymph 
node metastasis 
N3 Metastases in ipsilateral infraclavicular lymph nodes (level III), with or without level I and II 
axillary lymph node involvement, or  
Metastases in ipsilateral internal mammary lymph nodes and also in the level I and II axillary 
lymph node, or  
Metastasis in ipsilateral supraclavicular lymph nodes, regardless of  axillary or internal 
mammary lymph node metastasis 
Distant metastasis (M) 
M0 Not any evidence of distant metastasis 
cM0(i+) No clinical or radiographic evidence of distant metastasis, but evidence of tumor cells in 
circulating blood, bone marrow, or other non-regional lymph nodal tissue; with metastasis tumor 
size ≤ 0.2 mm and without any symptoms of metastasis 
M1 Clinical or radiographic evidence of distant metastasis, with/without histologically proven, 
metastatic tumor size >0.2 mm 
  11 
Histologic grade 
Another classification approach for breast cancer is based on the histologic grade, which 
represents the potential aggressiveness of the tumor. The Nottingham (Elston-Ellis) 
modification of the Scarff-Bloom-Richardson grading system is recommended for grading 
breast cancer [46]. According to mammary gland cell formation (or differentiation), the nuclear 
features (or pleomorphism) and the mitotic activity, breast tumors are classified as Grade I, II 
or III. Grade II tumors are classified with the lowest degree of concordance among different 
pathologists and therefore need to be sub-classified according to molecular profiling [46]. 
Molecular classification 
Breast cancer can be classified according to molecular receptor status, namely, estrogen 
receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor 
receptor 2 (HER-2) status, and Ki-67 index. 
Estrogen receptors are a group of proteins expressed in several human tissues and are activated 
by estrogen [47]. In breast cancer, the majority of ERs are ER-α, which is overexpressed by 
approximately 75% of breast cancer tumors [13]. The ER expression level is tested via 
immunohistochemical staining assay, and the cancer is categorized as ER positive when more 
than 10% of the cancer cells express ER. In 2010, this cut-off of 10% was changed to 1% [48], 
although patients with 1-9% of the cancer cells expressing ER still have worse survival than 
those with >10% of ER+ cancer cells [49]. A higher ER level is associated with improved 
survival after the patients are treated with endocrine therapy [50], while ER-negative cancer 
patients usually have a poor survival [51]. 
Another female hormone receptor, PR, also plays an important role in breast cancer 
development and prognosis. PR expression is strongly dependent on ER expression. PR is also 
tested using an immunohistochemical staining assay with a recommended cut-off of 1% [48]. 
Although a previous observational study showed better overall survival for PR+ and ER+ 
patients [52], a recent meta-analysis suggested that ER is the sole factor predicting endocrine 
treatment response without contribution from PR [53]. The function of PR in clinical prognosis 
prediction is still uncertain. 
HER-2 is expressed in many types of cancer [54]. HER-2 is a membrane tyrosine kinase that 
is associated with cell proliferation, survival, and apoptosis. Overexpression of HER-2 can be 
detected in 15-20% of breast cancer patients, and HER-2-positive patients are more likely to 
relapse and have poor survival [55]. HER-2 expression is also tested using an 
immunohistochemical staining assay, with tumors exhibiting HER-2 expression in >30% of 
cells categorized as HER-2 positive and those with <10% of cells expressing HER-2 as HER-
2 negative. For tumors with 10-30% cell staining, in situ hybridization assay is used to confirm 
the categorization [56]. 
Ki-67 is a nuclear non-histone protein showing proliferative activity of the tumor. The Ki-67 
level is measured as the percentage of tumor cells with positively stained nuclei. Currently, 
there is still no standard cut-off point for the Ki-67 level, although a 14% cut-off has been used 
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to differentiate Luminal A and B cancer [57]. A higher level of Ki-67 staining indicates a worse 
overall survival [58]. However, additional role of Ki-67 in breast cancer treatment and 
prognosis apart from other biomarkers is still uncertain [59]. 
Table 2.2. Molecular subtypes of breast cancer 
Molecular subtype Characteristics 
Luminal A ER and/or PR positive, HER-2 negative, Ki-67<14% 
Luminal B ER and/or PR positive, HER-2 negative, Ki-67 ≥14% 
Or: ER and/or PR positive, any Ki-67, HER-2 overexpressed or amplified 
Basal-like (triple negative) ER and PR negative, HER-2 negative 
HER-2-enriched HER-2 overexpressed or amplified, ER and PR negative 
Based on the genes that a tumor expresses, breast cancer can be divided into four molecular 
subtypes: Luminal A, Luminal B, HER-2-enriched, and basal-like cancer. Characteristics of 
these molecular subtypes are listed in Table 2.2 [60]. Among all breast cancer patients, 74% of 
cases are luminal A, 10% are luminal B, 12% are triple negative and 4% are HER-2-enriched 
[45]. Luminal A cancer is associated with better survival 5 years after diagnosis, albeit this 
effect attenuates over time [61].  
2.4 TREATMENT OF BREAST CANCER 
Treatment for breast cancer patients can be divided into i) local treatment to remove the 
tumor and stop its spreading, and ii) systemic treatment to kill micro site tumors and 
metastasis. Figure 2.7 shows standard treatment options for early stage breast cancer patients. 
Figure 2.7 Standard treatment options and procedures for early stage breast cancer patients 
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2.4.1 Local treatment 
Removing the tumor through surgery has been the primary treatment for breast cancer for about 
two centuries [62]. Mastectomy (removal of the entire breast) and lumpectomy (breast-
conserving surgery) are the two major surgical treatments for breast cancer. Mastectomy is 
aimed to excise invasive or non-invasive breast tumors with clear margins together with the 
whole breast, while in a lumpectomy, only a portion of the breast is excised. Recent studies 
have shown that patients treated with a lumpectomy followed by radiotherapy have the same 
survival outcome as those that underwent a mastectomy [63]. However, if the tumor is too large 
or there are multiple tumor sites, a mastectomy is still recommended [64]. The primary 
complications after breast surgery include pain, infection, and bleeding [65, 66]. Breast surgery 
is sometimes accompanied by an axillary lymph node dissection, which causes side effects 
such as lymphedema, pain and numbness of the upper limb [67]. The number of dissected 
lymph nodes is associated with a higher risk of infection and lymphedema in breast cancer 
patients and consequently impairs overall survival [68, 69]. To reduce these side effects and 
the hospital stay, the current technology of sentinel lymph node biopsy spares node-negative 
women from axillary lymph node dissection [70], and a maximum of 2 metastatic sentinel 
lymph nodes can be considered safe to avoid axillary dissection [71].  
In Sweden, radiotherapy is recommended for almost all early-stage breast cancer patients to 
prevent local recurrence in case tumor cells remain after surgery. Irradiation is usually applied 
to the remaining breast tissues and areas around the surgical margin, with a total dosage of 50 
grays. Radiotherapy after lumpectomy has been reported to reduce the risk of breast cancer 
recurrence by approximately 15% [72, 73]. Even for women with mastectomy, radiotherapy 
still reduces the risk of recurrence and mortality [74]. Although the irradiation is focused on 
the tumor site (or around the tumor site), currently, radiation-associated skin side effects still 
exist, such as dermatitis and psoriasis [75, 76]. Some long-term side effects, mainly lung cancer 
and ischemic heart disease, may occur 10-20 years after the treatment [77, 78]. 
2.4.2 Systemic treatment 
In the case of micro-metastasis to other sites in the body, chemotherapy is recommended after 
surgery to interrupt cancer cell proliferation and induce apoptosis. Breast cancer patients with 
lymph node involvement or ER-negative or HER-2-positive tumors are usually recommended 
for chemotherapy [79]. In Sweden, chemotherapy medicines for breast cancer primarily 
include 5-fluorouracil+epirubicin+cyclophosphamide (FEC), cyclophosphamide+ 
methotrexate+fluorouracil (CMF), and taxane-containing regimens (added when the tumor has 
metastasized to lymph nodes) [80, 81]. Anthracycline-based chemotherapy contributes to a 
one-third breast cancer mortality reduction in ten years after cancer diagnosis, and adding 
taxanes additionally reduces the mortality by 10% [82]. Chemotherapy agents indiscriminately 
interrupt cell proliferation, and thus, other cells with high proliferative activity are also 
damaged during the treatment period, causing a variety of side effects, including infection, 
neutropenia, anemia, nausea, diarrhea, malnutrition, and venous thromboembolism (VTE). 
[83]. In addition to these short-term side effects, chemotherapy also has long-term effects of 
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cardiac toxicity and neurotoxicity, potentially leading to heart failure and cognitive impairment 
later in life [84].  
Considering the high level of ER expression in breast cancer cells, endocrine therapy has been 
developed to prevent receptor activation and consequently to restrict tumor cell proliferation. 
There are two main medications for endocrine therapy: selective estrogen receptor modulators 
for all ER-positive patients and aromatase inhibitors (AIs) for postmenopausal ER-positive 
patients. Launched in 1975, tamoxifen is a selective estrogen receptor modulator that acts as 
an ER antagonist in breast tissue. Tamoxifen is usually prescribed to ER-positive patients for 
five years after cancer diagnosis and reduces breast cancer mortality by 30% [53]. The current 
international guideline suggests an extension of tamoxifen use for 10 years or switching to AIs 
for another 5 years [85]. AIs inhibit the aromatase enzyme in adipose tissues to prevent the 
conversion of androgens into estrogen. They reduce breast cancer recurrence and mortality by 
another 15% compared with the effect of tamoxifen [86]. These two types of medicines share 
certain side effects, such as hot flashes, weight gain, insomnia and fatigue. However, tamoxifen 
is an agonist that maintains endometrial polyp production and bone mineral density, and thus, 
more endometrial cancers and fewer bone fracture cases are observed in tamoxifen users [87, 
88]. 
In addition to chemotherapy and endocrine therapy, targeted therapy for breast cancer is aimed 
at blocking specific tumor development receptors or pathways. The most famous targeted drug 
for breast cancer, trastuzumab (or Herceptin), is a monoclonal antibody that targets HER-2. It 
is usually given to HER-2-positive breast cancer patients after chemotherapy for 1 year and 
improves the overall survival of these patients by 30% [89]. The major side effect of 
trastuzumab is cardiac toxicity; however, this is primarily a short-term effect [90]. Other drugs, 
which target VEGF, PARPs and immune checkpoints, are still in clinical trials to treat triple 
negative breast cancer [91]. 
2.5 PROGNOSIS OF BREAST CANCER 
As a result of the universal coverage of screening programs and therapy development, the five-
year survival rate for breast cancer patients has improved in the past three decades from 75% 
to 90% (Figure 2.8) [5]. Despite the improvement in prognosis, breast cancer patients still 
suffer from a decreased life expectancy after diagnosis compared with women of the same age 
[92, 93]. The cancer-associated factors for poor survival include stage, grade, hormone receptor 
status and HER-2 status, while accessibility to high-quality health care and socioeconomic 
status may also influence patient survival [94, 95].  
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Figure 2.8 Survival rate of breast cancer in Sweden (1970-2015) 
Data obtained from NORDCAN [5] 
In breast cancer patients, the 30-year cumulative mortality rate for breast cancer is 27%, while 
that for causes other than breast cancer is 48% [37]. Other important causes of mortality include 
cerebrovascular disease, cardiac disease, dementia and other cancers [96]. The probability of 
dying from breast cancer is quite high shortly after diagnosis, but the impact diminishes beyond 
1 year after cancer diagnosis [97]. Five-year survivors of breast cancer have a risk of dying 
from other diseases similar to that of the general female population [98].  
2.6 OTHER DISEASES ASSOCIATED WITH BREAST CANCER 
Due to the common genetic or environmental risk factors, as well as the side effects of 
treatment, breast cancer is associated with many other diseases. Some of the diseases are listed 
in Figure 2.9. These diseases are usually associated with poor overall survival, poor overall 
quality of life and higher health care cost for breast cancer patients [99-101]. Therefore, it is 
important to understand the panorama of diseases associated with breast cancer, i.e., how 
diseases in early adulthood influence the risk of breast cancer and how breast cancer treatments 
affect the overall health status of patients. 
2.6.1 Overview of diseases associated with breast cancer 
One third of breast cancer patients are comorbid with other chronic diseases at the time of their 
cancer diagnosis [102]. Among the five-year survivors of breast cancer patients, the proportion 
of patients comorbid with other diseases increases to 50%, and approximately 20% of these 
patients have more than two other diseases [98]. The most frequent diseases diagnosed in breast 
cancer patients include hypertension, cardiac disease, diabetes, and lung diseases [102]. Among 
the associated diseases before breast cancer diagnosis, benign breast disorders, diabetes and 
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other tumors are associated with an increased risk of breast cancer [103, 104], while 
preeclampsia and celiac disease are associated with a decreased risk [105, 106]. However, the 
risk of many other diseases increases after breast cancer diagnosis, including heart failure, bone 
fracture, infection, and coronary artery disease. Many of these diseases are caused by breast 
cancer treatment, for example, trastuzumab increases the risk of heart failure, while AIs 
increase the risk of bone fracture [88, 90].  
 
Figure 2.9 Selected diseases associated with breast cancer. 
The majority of studies in this field focus on specific diseases associated with cancer treatment. 
However, the effect of breast cancer treatment is sometimes systemic, and chronic diseases 
usually occur together because they share many risk factors. Consequently, many breast cancer 
patients have several other diseases. A current approach to studying a series of diseases in 
breast cancer patients is to use the Charlson comorbidity index (CCI), which includes 14 
diseases [107]. Nonetheless, these diseases are not specifically selected for breast cancer, and 
the acute effects of treatment, such as infection, neutropenia and VTE, are not included in the 
CCI. Therefore, it is important to have a comprehensive view of diseases associated with breast 
cancer, including both acute and chronic conditions. It would also be interesting to study the 
sequential association between treatment side effects and later life-threatening outcomes, 
which may help to identify key diagnoses to mitigate future poor outcomes. 
Before breast cancer diagnosis After breast cancer diagnosis 
…
 
…
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2.6.2 Preeclampsia 
 
Figure 2.10 Disruption of vascular remodeling in preeclampsia 
In a normal placenta (A), the vessel is compliant and blood flow from maternal side to placental spaces is enough, 
while in placenta of preeclampsia patients (B), the vessel walls remain stiff and the blood flow is limited. This 
figure is adopted from a publication of Pennington K., et., al [108]. FV, floating villi; AV, anchoring villi; ECTB, 
extravillous cytotrophoblast.  
Preeclampsia is a main course of maternal mortality and is characterized by hypertension and 
proteinuria [109]. Preeclampsia occurs in 3-5% of pregnant women and causes stroke, 
eclampsia, placental abruption and renal failure during pregnancy [110]. Pathophysiology of 
preeclampsia is characterized by disruption of vascular remodeling and systemic anti-
angiogenic response [108]. Evidence for the inverse association between preeclampsia and 
breast cancer has continuously been demonstrated since the 1980s [20, 106, 111, 112], but the 
mechanism of this association is still under discussion [113]. 
Some common risk factors may contribute to the inverse association between breast cancer and 
preeclampsia. A lower level of estrogen is observed in preeclampsia patients [114], indicating 
a lower level of exposure to endogenous hormones for the breast tissues. A high level of 
placental human chorionic gonadotropin (hCG) is also observed in preeclampsia patients[115]. 
In breast tissues, hCG has been shown to provoke mammary gland cell differentiation and 
inhibit breast cancer development [116, 117]. In addition, hCG could also induce insulin-like 
growth factor binding proteins (IGFBPs) and reduce the level of insulin-like growth factor-1 
(IGF-1) [118]. A low level of IGF-1 and a high level of IGFBPs are observed in preeclampsia 
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patients [119], while a higher level of IGF-1 is found in premenopausal breast cancer patients 
and in women with high mammographic density[120, 121].  
Placental ischemia is the key event in preeclampsia and is associated with a high level of 
soluble fms-like tyrosine kinase-1 [122]. A recent GWAS found an SNP near the FLT1 gene 
associated with preeclampsia risk, which is also associated with breast cancer risk [123, 124]. 
Candidate gene approach revealed approximately 70 genes that might be associated with 
preeclampsia, and several of the genes overlap with breast cancer risk genes, such as ACE, 
IGF1 and FLT1 [123, 125-127]. However, the results from different studies have been 
inconsistent, and thus, no universally acceptable risk gene has been defined for preeclampsia 
[128].  
 
2.6.3 Mental disorders 
Breast cancer patients are at increased risk of developing several mental disorders, including 
mainly depression, anxiety, and stress-related disorders [129]. These disorders do not only 
affect patients’ psychological well-being but might also influence work performance [130], 
treatment adherence [131, 132], and overall quality of life [133].  
The increased risk of mental disorders in breast cancer patients is to some extent a consequence 
of coping with the severe and stressful life event of cancer diagnosis. The hypothalamic-
pituitary-adrenal axis and sympathetic nervous system are considered to be the main players 
involved in the biological mechanism of the stress response, which releases hormones, such as 
corticotrophin-releasing hormone, adrenocorticotropic hormone and glucocorticoids [134]. A 
previous study showed associations between depression and adrenocorticotropic hormone and 
cortisol levels in breast cancer patients, supporting this potential pathway [135]. Late-stage and 
lymph node-positive tumors may result in a higher risk of mental disorders [136-138], 
suggesting a dosage effect of this stress response. Previous studies have shown a 70% increased 
risk of depression and anxiety in breast cancer patients [138-141]. However, the risk by time 
since diagnosis has rarely been described, despite the fact that the effect of the diagnosis may 
diminish over time, while treatments for cancer are given at different time points after 
diagnosis.  
Chemotherapy is the main treatment approach studied for the association between breast cancer 
and mental disorders. The side effects of chemotherapy (e.g., alopecia, nausea and vomiting) 
may be sufficiently stressful to increase the risk of depression and anxiety [142, 143]. However, 
some population-based studies did not find an impact of chemotherapy on depression and 
anxiety [138], likely because of the time-dependent effect of chemotherapy, which should be 
detectable only during and shortly after active treatment. 
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2.6.4 Psoriasis 
The risk of skin disorders, such as dermatitis and skin infection, is increased in breast cancer 
patients [68, 75]. However, the risk of psoriasis is less well studied, and previous analyses were 
mainly based on case reports [76, 144, 145]. Common symptoms of psoriasis include erythema 
and silver scaly plaques on the skin, but the severe subtype, arthropathic psoriasis, may result 
in joint deformation and disability. Psoriasis patients usually report a poor health-related quality 
of life and suffer from significant social stigma [146-148]. 
Psoriasis cases after breast cancer are mostly attributed to skin trauma induced by cancer 
treatments (surgery and radiotherapy) [76, 149]. Skin trauma (burns, scratches, bruises, cuts, 
etc.) has been reported to trigger approximately 43-76% of psoriasis cases [150], and an 
abnormal trauma healing process (keratinocyte differentiation and hyperproliferation) could 
contribute to the disease onset [151]. Moreover, as stressful life event is a risk factor for 
psoriasis [152], the increased risk of psoriasis in breast cancer patients might be the result of a 
psychological response to cancer diagnosis and treatment decisions.  
In addition to skin injury and psychological stress, psoriasis has some lifestyle risk factors, such 
as smoking, alcohol consumption and high BMI [153-155]. Streptococci infection and certain 
medications, such as lithium, beta-blockers and nonsteroidal anti-inflammatory drugs, may also 
increase psoriasis risk [156, 157]. 
2.6.5 Other important diseases associated with breast cancer treatment 
Adjuvant chemotherapy is very effective in reducing the risk of metastasis and mortality in 
breast cancer patients but also causes serious side effects, including neutropenia, infection, 
VTE, and cardiac disease [83]. Neutropenia in cancer patients is characterized as a temperature 
>38.5℃ and an absolute neutrophil count of <500 cells/ml [158]. Approximately 5.5-30.6% of 
breast cancer patients develop neutropenia after chemotherapy [83, 159], and chemotherapy 
regimens (especially taxane) are considered the main risk factor for neutropenia [160]. Other 
risk factors include age, comorbidity, BMI, baseline neutrophil count and genetic factors [161]. 
Preventive measures for neutropenia include maintenance of hygiene status and prophylactic 
use of antimicrobials (only recommended for high-risk patients) and Granulocyte colony 
stimulating factor [162, 163].  
Infection is a common complication in breast cancer patients. In addition to infection caused 
by the immunosuppressive effect of chemotherapy, skin infection is also common in breast 
cancer patients due to radiotherapy and lymphedema after axillary surgery [68]. Older age, 
comorbidities, and advanced cancer stage are independent risk factors for infection. Infection 
overall is associated with poor survival in cancer patients, especially for breast cancer patients 
with respiratory infection and sepsis [68]. 
VTE is a common outcome in cancer patients. The 1-year cumulative incidence of VTE is 
0.84% in breast cancer patients [164], and the risk increase persists for 10 years after cancer 
diagnosis [165]. There are several hypotheses for the incidence of VTE in cancer patients. The 
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development of a systemic hypercoagulable state is considered a key pathogenic process in 
VTE, and tumor production of procoagulants, fibrinolytic agents and pro-angiogenic cytokines 
could interact with vessels and blood cells to promote this process [166]. Apart from the tumor 
itself, surgery, endocrine therapy and chemotherapy are also associated with VTE risk in breast 
cancer patients [167].  
Cardiotoxicity is one of the long-term side effects of chemotherapy, likely because of the free 
radical-mediated myocyte damage caused by anthracyclines [168]. Radiotherapy for breast 
cancer usually causes some degree of incidental exposure of the heart to ionized radiation, 
consequently increasing ischemic heart disease risk [78, 169]. In addition, trastuzumab is also 
associated with an increased risk of cardiac disease and has a synergistic effect when combined 
with chemotherapy [170]. However, the risk does not outweigh the benefit of treatment [90], 
although cardiac disease is already the leading cause of mortality in breast cancer patients aside 
from the cancer itself [96].  
Endocrine therapy is given to breast cancer patients for at least 5 years and could cause diseases 
such as endometrial cancer and bone fracture. Long-term users of tamoxifen are at a higher risk 
of endometrial cancer, with a more advanced endometrial tumor type and worse survival [171]. 
Bone fracture is more frequently observed in patients treated with AIs because the peripheral 
antagonist action of AIs inhibits the formation of estrogen after menopause [88]. Older patients 
with more comorbid diseases are at increased risk of bone fracture [172]. Consequently, drugs 
such as bisphosphonates are prescribed to patients together with AIs to prevent bone loss and 
fracture [173]. 
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3 AIMS 
The overall aim of this thesis project was to describe the panorama of diseases associated with 
breast cancer and examine how these associations are influenced by genetic, patient, tumor and 
treatment characteristics. To reach the overall aim, four study goals were developed: 
1) To investigate the association between preeclampsia and breast cancer; 
2) To assess the time-dependent risk of depression, anxiety and stress-related disorders in 
breast cancer patients; 
3) To examine the risk and predictors of psoriasis in breast cancer patients; 
4) To investigate disease trajectories and mortality in breast cancer patients. 
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4 STUDY MATERIALS 
4.1 SWEDISH POPULATION AND HEALTH REGISTERS 
Sweden has a long history of collecting and registering population statistics since the 16th 
century, when the church started to keep information on local parish members. The first 
publication of population statistics was in 1749, and this publication became regular after the 
establishment of Statistic Sweden in 1858 [174]. From 1947 onwards, a personal identity 
number (PIN) has been used for every individual resident in Sweden, and this PIN contains 
information regarding an individual’s birth date and 4 additional digital numbers [175]. 
Currently, the National Tax Board holds full responsibility for creating the PIN and delivering 
the notifications to other administrations, including Statistic Sweden and National Board of 
Health and Welfare (Socialstyrelsen). These two agencies hold the majority of the population 
and health-related registers, and the PIN makes it possible to link these registers together to 
conduct nationwide population-based medical studies. Figure 4.1 shows the time line of 
different registers and two cohorts used in this thesis. 
 
Figure 4.1 Time line of the Swedish registers and the Libro-1 and KARMA cohorts 
The Total Population Register and the National Census 
The Total Population Register was constructed by Statistic Sweden in 1967 when it started 
collecting data from the local population registers. In 1991, Statistic Sweden handed the 
responsibility for the Total Population Register to the National Tax Board. The Total 
Population Register includes an individual’s date and place of birth, socioeconomic status, and 
address, among other information. In addition to the Total Population Register, the Swedish 
government also conducted a national population and housing census every decade (every five 
years since 1960) from 1860 to 1990. In 1995, the Swedish Parliament decided to change the 
census method by using a completely register-based approach, while previously, the general 
public needed to answer questionnaires [176]. The general population in this thesis were people 
who participated in the 1990 national census. 
The Swedish Multi-Generation Register 
Since 1961, a Multi-Generation Register was created to record child-parent (biological and 
adoptive) relationships in Sweden. As the personal record and PIN system was initiated in 1947 
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and a child’s parents were recorded in their personal record if the child was 15 years old or 
younger, only people who were born in 1932 or later are included in the Multi-Generation 
Register. The Swedish government used the 1960 census data as the basis of Multi-Generation 
Register, and people who were alive, born or immigrated to Sweden from 1961 onward were 
registered [177]. The Multi-Generation Register mainly contains the PIN and country of birth 
for the indexed person and their parents; the information on mothers has 97% coverage, while 
the information on fathers is 95%. Using the parental information, siblings of the index person 
can be found in the register and were used for Study I in this thesis. 
The Swedish Cause of Death Register 
The first attempt to collect mortality data at a population level in Sweden dates back to 1751. 
Before 1911, only certain important causes of death were included in the register, such as 
maternal mortality and suicide. From 1952 on, the Cause of Death Register became 
electronically available, and the underlying cause of death was coded according to the World 
Health Organization standards, the International Statistical Classification of Diseases and 
Related Health Problems (ICD). The Cause of Death Register has an almost 100% 
completeness, and only 0.9% of the underlying cause of death information is missing [178]. 
However, the overall concordance between the disease registered on the death certificate 
registration and the medical record for hospital-based mortality is approximately 77%, but is 
quite high for cancer (92%) [179]. 
The Swedish Patient Register 
The advantage of performing medical research in Sweden is partly due to the good coverage 
of the Patient Register, which allows complete follow-up of individuals to detect disease 
incidence. The Swedish Patient Register started in 1964/1965 and reached complete coverage 
in 1987. Since 2001, outpatient hospital visits are also recorded in the Patient Register, which 
has a coverage of approximately 80% (visits to public hospitals have almost 100% coverage). 
Primary and contributory diagnoses for patients are coded according to the Swedish Version 
of ICD codes (1964-1968: ICD-7; 1969-1986: ICD-8; 1987-1996: ICD-9; 1997 to present: 
ICD-10). Overall, primary diagnosis is found in 99% of all the hospital discharges, and the 
positive predictive values for the diagnosis codes are 85- 95% based on the 3-digit codes [180]. 
The Swedish Prescribed Drug Register 
The Prescribed Drug Register was recently established in July 2005 and covers all counties in 
Sweden [181]. It is an automatic register containing information on prescribed drugs dispensed 
at the pharmacy, including the prescribed date, pick-up date, drug name, and the dosage and 
amount of drug. The drug names are coded according to the anatomical therapeutic chemical 
classification system. Of note, drugs used in the inpatient ward and over-the-counter drugs are 
not recorded in this register. 
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The Swedish Medical Birth Register 
Since 1973, information on maternal deliveries and newborn infants has been recorded in the 
Medical Birth Register held by the National Board of Health and Welfare, which has a coverage 
of 99% of the births in Sweden [182]. Starting from 1982, the information has been collected 
through copies of antenatal, obstetric and pediatric medical records. The antenatal record is 
collected by the midwife from the first antenatal visit (at approximately 8-12 weeks gestation) 
and includes height, weight, smoking status and previous reproductive history. The obstetric 
and pediatric records are reported by the clinician when the mother is discharged from the 
hospital after delivery and include complications and mode of delivery, as well as the 
gestational age, birth weight, Apgar score and infant diagnosis for the child. Complications 
during pregnancy and delivery are also coded according to the Swedish version of the ICD, 
and the quality of the antenatal and obstetric records is considered high [183]. 
The Swedish Cancer Register 
To monitor cancer incidence in Sweden, the Swedish Cancer Register was established in 1958 
to collect information on cancer diagnosis and tumor stage (from 2004). Swedish physicians 
and pathologists are obliged to report the information to the Cancer Register when they 
diagnose a cancer, regardless of whether the tumor is benign or malignant. The completeness 
of the Cancer Register is considered to be 100% [184]. The Cancer Register is tumor-based, 
and thus, bilateral breast tumors are entered into the register separately. The completeness and 
correctness of invasive breast cancer information in the Cancer Register are considered to be 
99% and 96%, respectively, while those for in situ cancer are 95% and 96% from the 
assessment in the 1990s [185]. 
The breast cancer quality register  
Although the Swedish Cancer Register provides a good record of all sites of cancer in Sweden, 
detailed information for specific cancer types is not included. Since 1970s, the six regions of 
Sweden started to establish their own breast cancer quality registers [186], and in 2007, all 
these quality registers were combined into a national breast cancer quality register (Information 
Network for Cancer treatment, INCA). Since the studied breast cancer patients cover both 
periods, INCA and the breast cancer quality register in Stockholm and Gotland Regional 
Cancer Center are used in this thesis. The accuracy (concordance) of tumor characteristics 
(especially ER and PR status) and recommended treatment information in the breast cancer 
quality register is considered to be 92-96% [187, 188]. 
In addition to these registers, we also used information from some population registers, such 
as the Education Register and Migration Register, to retrieve information on education level 
and to censor the follow-up of individuals at emigration. 
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4.2 THE LIBRO-1 COHORT 
The Linne bröst 1 (Libro-1) cohort consists of all the breast cancer patients diagnosed in the 
Stockholm-Gotland region between 2001 and 2008 according to the regional breast cancer 
quality register. For those patients with an available address and alive in 2009, an invitation to 
participate in the study was sent by letter, and 61% of them consented to be involved. For the 
entire Libro-1 cohort in the quality register, we linked the patients to the Swedish Cause of 
Death, Patient, Migration, Prescription and Cancer Registers. For those who consented to 
participate, we also sent a questionnaire seeking information about various breast cancer risk 
factors, such as family history, lifestyle and reproductive factors. At the time of invitation, two 
EDTA-buffered blood-sampling tubes and transportation kits were also provided, and the 
participants were asked to go to the local clinic for blood collection. The blood samples were 
sent to UK for genotyping by use of an Illumina iSelect SNP Array (iCOGS, comprising 
211,155 SNPs) [189]. The missing genotypes were imputed using the 1000 Genomes Project 
March 2012 release as a reference. 
4.3 THE KARMA COHORT 
The KARolinska MAmmography project for Risk Prediction of Breast Cancer (KARMA) is a 
screening-based cohort formed through an invitation to all women participating in a 
mammographic screening or clinical mammography in four hospitals in Sweden (Stockholm 
South Hospital, Helsingborg Hospital, Skåne University Hospital and Landskrona Hospital) 
between January 2011 and March 2013 [29]. During the recruitment period, 70,877 women 
consented to join the study, and 97% of them completed a web-based questionnaire containing 
approximately 250 questions related to breast cancer, such as family history, lifestyle, diet, and 
quality of life questions. Mammograms of the participants were collected continuously each 
time they underwent mammography in these hospitals from the baseline. All the KARMA 
participants donated their blood in the hospital after they consented. Approximately 2700 breast 
cancer patients and 6400 controls in the KARMA cohort were genotyped with an Illumina 
Infinium OncoArray assay, comprising 499,170 SNPs[10], while more than 5000 other 
controls were genotyped using iCOGS (selected as controls for the genotyped breast cancer 
patients in the Libro-1 cohort) [189]. The missing genotypes were also imputed using the 1000 
Genomes Project March 2012 release as a reference. 
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5 STUDY DESIGNS AND METHODS 
5.1 OVERVIEW OF THE DESIGNS AND METHODS USED IN THE THESIS 
To investigate the association between other diseases and breast cancer, we used several 
study designs and methods. An overview of these methods is presented in Table 5.1. 
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5.2  STATISTICAL METHODS USED IN THE THESIS 
5.2.1 Survival analysis and models 
Survival analysis is usually performed for the time-to-event outcomes in a cohort. Two main 
variables should be measured in the survival analysis: one is the duration from study entry to 
the end of event occurrence, and the other is the event indicator to show the outcome status. If 
the individual drops out or cannot be followed or the specific event does not occur when the 
study ends, the event is right censored, and the indicator is considered 0. In this thesis, we used 
different survival analysis models to test the association between breast cancer and other 
diseases. 
Kaplan-Meier estimator and cumulative incidence 
The central concept of survival analysis is based on the survival function S(t), the probability 
of survival until time t. There are several parametric and nonparametric approaches to estimate 
the survival function. The Kaplan-Meier method is one of the most common nonparametric 
approaches and calculates the probability of survival each time the event occurs and multiplies 
these probabilities. 
The cumulative incidence is defined as the probability of an event occurring within a given 
time and can be calculated as 1-S(t). Hence, the Kaplan-Meier method can be extended to 
calculate cumulative incidence. 
Standardized incidence ratio 
To measure the risk of disease occurrence, an incidence rate or incidence density is usually 
calculated by dividing the number of events by the person-times at risk. A ratio of the incidence 
rates can then be interpreted as the effect of exposure on the disease occurrence, compared with 
the control group. Sometimes, if there is no control group for analysis or the comparison group 
is the general population, a standardized incidence ratio (SIR) could be an alternate parameter 
to assess the effect of exposure. The SIR divides the observed number of events by the expected 
number of events. The expected number of events is calculated by multiplying the number of 
person-time observed in specific strata of the exposure group by the incidence rates of the 
disease outcomes in the corresponding strata of the general population. In this thesis, we have 
the national census data, and the incidence rates of diseases were therefore directly calculated 
from the registers. Calculation of the confidence interval (CI) is based on the Poisson 
distribution. 
Poisson regression model 
The Poisson regression model is a type of generalized linear model that assumes the log rate of 
event incidence to be linearly related to the explanatory variable. When used in survival 
analysis, Poisson regression estimates the baseline incidence rates and calculates the incidence 
rate ratio (IRR) for comparison of different groups. Poisson regression can also address the 
multiple time scales problem in the survival analysis by splitting the record according to 
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different time-scale intervals. Follow-up time splitting can also be used to analyze time-varying 
effect of the exposure by splitting the record at the exposed time point and the exposed person-
time was counted from this time point.  
Cox regression model 
The Cox proportional hazard model is the most frequently used survival model in medical 
research. It compares the hazard of an event in the exposed group to the hazard in the unexposed 
group, and a hazard ratio (HR) is estimated to assess the effect of exposure on the event 
occurrence. Cox regression assumes the hazard to be proportional over time, which should be 
checked using tests, such as the Schoenfeld residuals test. For matched cohort data, an 
extension of the Cox model, stratified Cox regression, is recommended to condition the 
matching variables and to address the presence of potential confounders as well as the 
imbalances in matching scheme caused by censoring [190, 191]. It is a conditional model for 
ordinary Cox regression, similar to the conditional logistic regression for the ordinary logistic 
regression model.  
Flexible parametric model 
The flexible parametric model is a restricted cubic spline-based model for survival analysis 
[192]. It is fitted according to the cumulative hazard function (a negative logarithm for the 
survival function) in the log scale using a cubic spline. In the model, the cubic spline is 
restricted to be linear outside the first and the last splining knots. For a large-scale dataset (e.g., 
the population-based studies in this thesis), five to six knots are recommended to put into the 
model. At this step, the flexible parametric model is similar to the Cox model, in which the 
proportionality of hazard is still assumed, and provides an overall estimation of the HR. In a 
further step, an interaction term between covariate (x) and time using a second spline function 
can be added into the model, and the effect of covariate x is then dependent on time. The 
number of knots in the second spline function should be less than the knots used in the first 
spline, and the number is recommended to be 3 to 4. This technique allows us to analyze the 
time-dependent risk profile of specific exposure when the proportional hazard assumption does 
not hold. 
5.2.2 Logistic regression model 
The logistic regression model is commonly used when dealing with binary outcomes in medical 
research. The model uses a logarithm transformation for the odds of outcome events and fits a 
linear model to the explanatory variables. Estimation of the coefficient is performed with a 
maximum likelihood approach, and the exponential of the coefficient is the odds ratio (OR), 
interpreted as the odds of being a case in the exposed group compared with the unexposed 
group. The logistic regression model is usually used in studies with case-control design. 
In the special occasion of an individually matched case-control design, the conditional logistic 
regression model is used to estimate the OR. This model assumes a constant OR across the 
matched strata and controls the matching variables by conditioning. 
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5.2.3 Linear regression model 
A linear regression model is used to assess the effect of exposure on continuous outcomes, 
while the exposure could be continuous or categorized. An ordinary least square approach is 
usually used to estimate the best fitted linear function (Y=β0+∑βixi+ε) describing the change 
in outcome by one unit change in the exposure. The linear regression model has four major 
assumptions (LINE): (i) Linearity between the exposure and the outcome; (ii) Independence 
between the error variable ε and exposure xi, and the mean of ε should be zero; (iii) Normal 
distribution of Y for any exposure xi; and (iv) Equal variance (homoscedasticity) for the errors 
in outcome variables, given different values of exposure variable. 
If the normality and homoscedasticity assumptions do not hold, the ordinary least square 
estimation for the standard error of β will be problematic. In this scenario, a sandwich variance 
estimator could be used to release these two assumptions.  
5.3 SPECIFIC DESIGN FOR EACH STUDY 
5.3.1 Association between preeclampsia and breast cancer 
To assess the risk of breast cancer in women diagnosed with preeclampsia, we included two 
cohorts: a Swedish nationwide cohort of pregnant women and women with a child in the 
KARMA cohort (Aim 1 in Figure 5.1). The nationwide cohort was retrieved from the Swedish 
Medical Birth Register and included all women who delivered their first child between 1973 
and 2005 (n=1,337,934). Pregnancy characteristics, such as BMI, smoking status, maternal age 
and previous reproductive history, as well as preeclampsia diagnosis, are included in the 
register. The preeclampsia diagnosis was recorded according to ICD codes as follows: ICD-10: 
O14 and O15; ICD-9: 642E, 642F and 642G; and ICD-8: 63703, 63704, 63709, 63710 and 
63799. For the KARMA cohort, information on preeclampsia diagnosis was asked in the 
questionnaire. In this study, we only included women who had delivered their first child after 
1958 and completely answered the questionnaire (n=55,044). Follow-up for both of the cohorts 
started from the birth date of each woman’s first child and ended on the date of the first breast 
cancer diagnosis, emigration date, date of death or end of follow-up (December 31, 2011 for 
the nationwide cohort and February 28, 2015 for the KARMA cohort), whichever came first. 
Information on breast cancer diagnosis, emigration, and death was obtained by linking these 
two cohorts to the Swedish Cancer Register, Swedish Migration Register and Swedish Cause 
of Death Register.  
The Poisson regression model was used to calculate the IRR of breast cancer in women 
diagnosed with preeclampsia compared with women without preeclampsia. The underlying 
time scale for this analysis was attained age. We constructed two models to test the effect of 
preeclampsia diagnosis on breast cancer risk: a basic model adjusting for calendar period and 
a multivariable model additionally adjusting for the number of births, age at first birth, BMI 
categories, and educational level in the nationwide cohort. For the KARMA cohort, the 
multivariable model was also adjusted for alcohol use, age at menarche, physical activity at 18 
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years old, body shape at 18, and irregular menstrual cycles in adult life. We also estimate the 
risk of ER+ and ER- breast cancer separately in the KARMA cohort. 
Figure 5.1 Materials and methods used in the study for preeclampsia and breast cancer 
To identify the genetic association between preeclampsia and breast cancer, we linked both 
cohorts to the Swedish Multi-Generation Register and retrieved information regarding the 
women’s sisters (Aim 2 in Figure 5.1). In the nationwide cohort, we used the logistic regression 
model to calculate the ORs of preeclampsia among cancer-free sisters of the breast cancer 
patients compared with cancer-free women without breast cancer sisters. In the KARMA 
cohort, blood samples from a subset of 9263 women without breast cancer were genotyped, 
and we selected 171 genome-wide significant SNPs to construct a PRS [10]. The PRS was 
calculated as follows: PRS =  x  x        k x k nx n ,  where   is the per-allele log 
OR of a breast cancer-associated risk allele for SNP k, xk is the number of alleles for the same 
SNP (0, 1, 2), and n is the total number of the disease SNPs included in the profile. In this 
analysis, we calculated the OR of preeclampsia by different percentiles of the PRS (0-40%, 40-
60%, 60-80%, 80-90% and 90-100%). For both of the analyses, we adjusted for number of 
births, age at first birth, BMI categories, smoking status and education in a multivariable model. 
Aim 1: Risk of breast cancer in preeclampsia patients 
Nationwide cohort of pregnant women 
(1973-2011, N=1,337,934)
Exposure: preeclampsia diagnosis 
(Medical Birth Register)
Outcome: breast cancer (Cancer 
Register)
Statistics:  Poisson regression, 
incidence rate ratio
KARMA mammographic screening cohort 
(1958-2015, N=55,044)
Exposure: preeclampsia history 
(questionnaire data )
Outcome: breast cancer (Cancer 
Register)
Statistics:  Poisson regression, 
incidence rate ratio
Aim 2: Genetic association between preeclampsia and breast cancer 
Sisters in nationwide cohort of pregnant 
women (N=644,483)
Exposure: Sister history of breast cancer 
(Multi-Generation and Cancer Register)
Outcome: preeclampsia diagnosis 
(Medical Birth Register)
Statistics:  Logistic regression, odds 
ratio
Genotyped KARMA women (N=9,263)
Exposure: Polygenic risk score for  
breast cancer (blood sample)
Outcome: preeclampsia diagnosis 
(questionnaire data )
Statistics:  Logistic regression, 
odds ratio
Aim 3: Association between preeclampsia and mammographic density 
Non-cancer KARMA women (N=43,844)
Exposure: personal or sister history of 
preeclampsia (questionnaire)
Outcome: mammographic density
Statistics:  Linear regression
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Considering mammographic density as an intermediate phenotype of breast cancer, we also 
tested the association between percentage density and previous preeclampsia diagnosis in the 
KARMA cohort (Aim 3 in Figure 5.1). In this analysis, women with any previous cancer or 
any breast surgery were excluded, leaving 43,844 women. We used the linear regression model 
with a robust sandwich estimator for the standard error. We adjusted for age at mammogram, 
BMI categories, age at menarche, number of births, age at first birth, menopausal status at 
mammogram, irregular menstrual cycle, physical activity at 18, body shape at 18, education 
level, smoking status, and alcohol consumption. We also tested the genetic association between 
preeclampsia and mammographic density by selecting the women in the cohort who have a 
sister (n=3500) and investigating the difference in mammographic density in sisters of patients 
with preeclampsia compared with women without a preeclamptic sister. 
5.3.2 Time-dependent risk of mental disorders in breast cancer patients 
To assess the risk of depression, anxiety and stress-related disorders in breast cancer patients, 
we used the Swedish Cancer Register to identify all the women diagnosed with primary 
invasive or in-situ breast cancer at an age range of 20-80 between 2001 and 2009 (n=50,652). 
We linked the cohort to the Swedish Patient Register to obtain information on main diagnoses 
of mental disorders according to ICD-10 codes: depression (F32 and F33), anxiety (F40 and 
F41) and stress-related disorders (F43) (Figure 5.2). We also excluded patients who had a 
history of mental disorders [ICD-10: F0-F4; ICD-9: 290-300, 303-306, and 308-311; and ICD-
8: 290-300, 303-305, 307, and 309] to ensure an analysis focusing on the new-onset cases, 
leaving 40,849 patients with invasive and 4402 patients with in-situ breast cancer in the cohort. 
Follow-up of this cohort started from the date of breast cancer diagnosis and ended on the date 
of the first mental disorder, death, emigration, a new cancer diagnosis or end of follow-up 
(December 31, 2010). Information on death and emigration was obtained through linking the 
cohort to the Swedish Cause of Death and Migration Register. We compared the risk of 
depression, anxiety and stress-related disorders in invasive and in-situ breast cancer patients to 
that in the general population by calculating SIRs, overall and stratified by time since cancer 
diagnosis. Standardization was performed according to the age, calendar period and region of 
residence of the individuals.  
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Figure 5.2 Linkage of registers to obtain exposures and outcomes for mental disorder study 
To identify the risk factors for mental disorders in breast cancer patients, we constructed a 
Stockholm-Gotland regional cohort of invasive breast cancer patients (n=7,940, 2001-2008, at 
age 20-80), using the Libro-1 cohort. Patient, tumor and treatment characteristics of the breast 
cancer patients were extracted from the breast cancer quality register, including age at diagnosis, 
tumor size, histological grade, ER status, axillary lymph node involvement, distant metastasis, 
chemotherapy, endocrine therapy, radiotherapy and surgery. Information on comorbidities 
before breast cancer diagnosis was assessed by the CCI [107] using hospital discharge 
diagnoses from the Swedish Inpatient Register. Follow-up for this regional cohort was similar 
to that for the nationwide cohort, except for an extension of follow-up to December 31, 2013. 
The flexible parametric model was used to estimate the effect of these patient, tumor and 
treatment characteristics on the risk of mental disorders by calculating HRs. The proportional 
hazards assumption was tested using a likelihood ratio test, adding the time by covariate 
interaction term. In the case of non-proportionality, the time by covariate interaction term was 
kept in the model, and the effect of this covariate was reported at different time points since 
diagnosis. The underlying time scale for these analyses was time since diagnosis and a 
multivariable model including all these covariates was used.  
5.3.3 Predictors of psoriasis in breast cancer patients 
Since previous studies suggested a possible increased risk of psoriasis in breast cancer patients, 
we constructed a nationwide cohort of invasive breast cancer patients diagnosed between 2001 
and 2011 to test this hypothesis (n=56,235). These patients were retrieved from the Swedish 
Cancer Register, and patients with a psoriasis diagnosis prior to cancer diagnosis were excluded. 
For risk comparison, we matched these patients with up to 5 non-cancer individuals from the 
general population according to age, county of residence and social-economic status (obtained 
from the 1990 national census). These reference individuals were free of cancer and psoriasis 
on the date of the matched patients’ date of breast cancer diagnosis (the index date). In total, 
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we matched 280,852 reference individuals for these breast cancer patients. For both cohorts, 
the psoriasis diagnosis was obtained by linking the cohorts to the Swedish Patient Register and 
was identified by the main diagnosis using ICD codes: 706 (ICD-7), 696 (ICD-8 & 9) and L40 
(ICD-10). The first psoriasis diagnosis was further sub-grouped into psoriasis vulgaris (L40.0), 
palmoplantar pustulosis (L40.3), arthropathic psoriasis (L40.5) and others (L40.1, L40.2, L40.4, 
L40.8, L40.9). Follow-up of both the cohorts started from the index date and ended on 
December 31, 2012, date of death, date of emigration, date of a secondary cancer diagnosis or 
date of psoriasis diagnosis, whichever came first. We used stratified Cox regression models to 
calculate HRs for psoriasis in breast cancer patients compared with the matched reference 
individuals, overall and by time since diagnosis.  
To identify the risk factors for psoriasis in breast cancer patients, we again used the Libro-1 
cohort as a regional breast cancer patient cohort, similar to the cohort for the mental disorder 
analysis in Study II, with the same follow-up scheme. In addition to the patient, tumor and 
treatment characteristics obtained from the breast cancer quality register, a subset of 4365 
patients were alive in 2009 and consented to participate in the questionnaire survey and blood 
donation. Information on smoking status, BMI, alcohol consumption and physical activity prior 
to diagnosis was obtained from the questionnaire. Genotyping of the blood samples was 
performed and we selected 35 GWAS significant SNPs for psoriasis to construct a PRS [193]. 
The PRS calculation procedure was similar to the calculation for the breast cancer PRS in Study 
I, and the PRS was grouped into tertiles. An ordinary Cox regression model was used to test 
the association between cancer treatment and psoriasis risk, adjusting for age at cancer 
diagnosis, calendar period, and all the treatment characteristics. The effect of genetic 
predisposition and lifestyle factors were also tested in a model adjusting for age, calendar 
period and significant treatment risk factors in addition to the genetic and lifestyle factors. The 
proportional hazard assumption was tested using Schoenfeld residuals. 
5.3.4 Disease trajectories and mortality in breast cancer patients 
To study the disease trajectory (a sequential association of disease occurrences) and mortality 
among breast cancer patients, we identified 57,501 patients diagnosed with primary invasive 
breast cancer between 2001 and 2011, aged 20-80 years, from the Swedish Cancer Register 
(Figure 5.3). To compare the incidence and mortality of other diseases, we randomly sampled 
up to 10 women from the Swedish population as controls. The matching criteria included age, 
county of residence and social economic status. Each control individual was alive and free of 
breast cancer two months after the matched patient’s cancer diagnosis (the index date), 
resulting in 564,703 matched controls. Disease incidence and mortality were coded according 
to the ICD codes. All diseases in this study were defined based on the 3-digit ICD-10 codes 
(A00 to N99) obtained from the primary and contributory diagnoses in Patient Register. We 
additionally combined several ICD codes considering their biological and clinical similarity 
(e.g., combining F40 and F41 for anxiety). Other cancer diagnoses were obtained from Swedish 
Cancer Register. Only those diseases with more than 100 cases among breast cancer patients 
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were included for analysis. The same range of diseases was tested for the mortality risk using 
only the underlying cause of mortality from Cause of Death Register. 
Follow-up of the entire cohort started from the index date and ended on December 31st, 2012 
(December 31st, 2011, for other cancer incidences), date of emigration, date of death, or date 
of the studied disease incidence (or mortality), whichever came first. Individuals with disease 
diagnosis before the index date were excluded when analyzing that specific disease. A 
phenome-wide association study (PheWAS) [194] was performed to assess disease incidence 
and mortality among breast cancer patients, compared with matched controls. PheWAS was 
previously used to reveal unknown associations between a specific gene and phenotypic 
features (e.g., electronic medical records) in a hypothesis-free approach. We extended this 
method to assess the association between breast cancer and a range of diseases after cancer 
diagnosis. For each disease, a matched-cohort analysis was performed using a stratified Cox 
regression model. The significant p-values were therefore identified according to Bonferroni 
correction. 
 
Figure 5.3 Flow chart of the design and methods for disease trajectories and mortality 
analyses. 
Disease trajectories were studied using binomial tests to assess the sequential directionality for 
a pair of diseases (D1→D2) and ORs to measure the strength of the association [195]. Only 
diseases with significantly increased incidence after breast cancer diagnosis and disease pairs 
(D1→D2) with more than 50 cases of D2 after D1 were involved in the test. Patients with either 
D1 or D2 before the start of follow-up were excluded. We defined breast cancer patients with 
Swedish national cohort 
of breast cancer patients  
(n=57,501, 2001-2012) 
1:10 controls from general female population, matching on 
age, county of residence and socioeconomic status (n=564,703) 
Patient/Cancer register 
Cause of death register 
Diseases with increased incidence  
Diseases with increased mortality  
Build up candidate disease pairs (D1→D2) 
using Patient/Cancer register 
Binomial test for directionality of 
disease pairs 
Conditional logistic regression for 
strength of disease pairs 
Breast cancer patients with D2 as cases 
1:5 breast cancer patient controls without D2, matched 
on age and year of diagnosis, county, and 
socioeconomic status, using incidence density sampling 
Disease pairs with increased risk of 
D2 after D1 
Find 20 patients to support the 
trajectories leading to mortality 
Map out the trajectories leading to mortality 
PheWAS analysis 
Disease trajectory 
+ 
Method 
Data 
Outcome 
Cox regression 
Cox regression 
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D2 as cases and matched them with 5 patient controls using incidence density sampling. The 
matching criteria included age at breast cancer diagnosis, year of breast cancer diagnosis, 
county of residence and social economic status. The conditional logistic regression model was 
used to calculate the ORs, and the threshold of p-values was set according to Bonferroni 
correction. Significant disease pairs passing the directionality and association tests with OR>1 
were combined into disease trajectories. Those disease pairs with more than 20 cases leading 
to mortality were valid and mapped separately according to the cause of mortality.  
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6 RESULTS 
6.1 ASSOCIATION BETWEEN PREECLAMPSIA AND BREAST CANCER 
In both the nationwide cohort of pregnant women and the KARMA cohort, approximately 5-
6% of women had been diagnosed with preeclampsia, and older age at first birth, more parities, 
higher BMI and smoking were associated with preeclampsia in a univariate test. In the 
nationwide cohort, 27,626 women developed breast cancer during the follow-up, 
corresponding to an age-adjusted incidence rate of 1.5/1000 person-years, while in the 
KARMA cohort, 2496 women developed breast cancer at the end of follow-up, corresponding 
to an age-adjusted incidence rate of 3.0/1000 person-years. 
We found a decreased risk of breast cancer after preeclampsia diagnosis in both the nationwide 
(IRR=0.90, 95% CI=0.85; 0.96) and KARMA cohort (IRR=0.75, 95% CI=0.61; 0.93). The 
reduced risk of breast cancer was even lower in women with two or more occurrences of 
preeclampsia (Table 6.1). However, the risks of ER+ and ER- breast cancer in the KARMA 
cohort were similar (IRR for ER+=0.80, 95% CI=0.61; 1.05 and IRR for ER-=0.76, 95% 
CI=0.36; 1.62), suggesting this association between preeclampsia and breast cancer did not 
differ according to ER status. 
Table 6.1. Association between preeclampsia and breast cancer among nationwide cohort 
and KARMA cohort 
Condition 
No. of breast 
cancer cases 
IRR (95%CI) 
Model 1 Model 2 
Nationwide cohort (N=1,337,934) 
Pre-eclampsia     
    No 26447 1.00  (REF) 1.00  (REF) 
    Yes 1179 0.88 (0.83;0.94) 0.90 (0.85;0.96) 
         once 1082 0.90 (0.84;0.95) 0.91 (0.86;0.97) 
         multiple times 97 0.76 (0.62;0.92) 0.81 (0.66;0.99) 
KARMA cohort (N= 55,044) 
Pre-eclampsia     
     No 2410 1.00  (REF) 1.00  (REF) 
     Yes 86 0.77 (0.62;0.95) 0.75 (0.61;0.93)* 
Abbreviations: IRR=Incidence rate ratio; CI=Confidence interval.  Model 1 adjusted for calendar period (10-year 
categories); Model 2 further adjusted for number of births, age at first birth, weight status categories, smoking 
status and education level. The underlying time scale was attained age. 
* For Model 2 using the KARMA cohort, we additionally adjusted for alcohol use, age at menarche, body shape 
at age 18, physical activity at age 18, and irregular menstrual cycles in adult life. 
To test whether inherited factors contributed to the inverse association between breast cancer 
and preeclampsia, we first investigated the familial aggregated association between these two 
diseases. In cancer-free sisters of the breast cancer patients in the nationwide cohort, the risk 
of preeclampsia was reduced by 11% (OR=0.89, 95% CI=0.83; 0.96). Another attempt to show 
genetic association in the KARMA cohort indicated that women with the highest 10% of PRS 
 38 
for breast cancer were less likely to develop preeclampsia during their pregnancy (OR=0.56, 
95% CI=0.36; 0.86. Figure 6.1).  
 
Figure 6.1. Association between genetic predisposition to breast cancer and preeclampsia in 
women without breast cancer 
Abbreviations: No.=Number; PE=Preeclampsia; OR=Odds ratio; CI=Confidence interval; PRS=Polygenic risk score. 
Considering mammographic density as a proxy of breast cancer, we also analyzed the 
association between preeclampsia and percentage mammographic density. In the 43,844 
women available for density analysis, 2261 had a previous diagnosis of preeclampsia. These 
preeclampsia patients had a lower density (-2.04%, 95% CI=-2.65;-1.43) compared with 
women without preeclampsia in the multivariable adjusted model. When testing the familial 
aggregated association between preeclampsia and density among the 3500 women with 
available sister information in the cohort, sisters of the preeclampsia patients also had a lower 
mammographic density than women without a preeclampsia sister (-2.76%, 95% CI=-4.96; -
0.56). 
6.2 TIME-DEPENDENT RISK OF MENTAL DISORDERS IN BREAST CANCER 
PATIENTS 
  
Figure 6.2 Risk of depression, anxiety and stress-related disorders in the nationwide breast 
cancer cohort, compared with general female population 
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In the nationwide cohort of breast cancer patients, the 5-year cumulative incidences of 
depression, anxiety and stress-related disorders in invasive cancer patients were 2.1, 1.5 and 
1.1%, respectively, while those for in-situ patients were 1.4, 1.1 and 0.7%. Invasive cancer was 
associated with an increased risk of mental disorders compared with the risk in the general 
population, with similar SIRs for depression (SIR=1.57, 95% CI=1.46; 1.69), anxiety 
(SIR=1.55, 95% CI=1.43; 1.68) and stress-related disorders (SIR=1.77, 95% CI=1.60; 1.95). 
The increased risk of these mental disorders was highest in the first year after cancer diagnosis 
and remained increased for five years (Figure 6.2). However, the in-situ breast cancer patients 
did not experience an overall risk increase for mental disorders after cancer diagnosis, except 
for an increased risk of stress-related disorders during the first half year (SIR=2.76, 95% 
CI=1.31; 5.79). 
Table 6.2 Hazard ratios of depression, anxiety and stress-related disorders according to 
patient, tumor and treatment characteristics in the regional breast cancer cohort.  
 
Total 
No. 
Depression  Anxiety  Stress-related disorder 
No. HR (95% CI)  No. HR (95% CI)  No. HR (95% CI) 
Patient characteristics          
Age at diagnosis 
         
23-44 years 1012 86 REF (1.00) 
 
114 REF (1.00) 
 
47 REF (1.00) 
45-54 years 1913 115 0.77 (0.58; 1.03) 
 
109 0.53 (0.41; 0.69) 
 
64 0.70 (0.48; 1.03) 
55-64 years 2629 80 0.40 (0.30; 0.55) 
 
86 0.32 (0.24; 0.43) 
 
26 0.20 (0.12; 0.33) 
65-80 years 2386 54 0.33 (0.23; 0.47) 
 
53 0.22 (0.16; 0.32) 
 
10 0.09 (0.04; 0.18) 
Comorbidities †     
  
  
  
  
 
No 6797 287 REF (1.00) 
 
304 REF (1.00) 
 
128 REF (1.00) 
Yes  1143 48 1.44 (1.05; 1.97) 
 
58 1.67 (1.25; 2.23) 
 
19 1.49 (0.91; 2.44) 
Tumor characteristics   
         
Size in mm 
         
  <10 1867 71 REF (1.00) 
 
69 REF (1.00) 
 
37 REF (1.00) 
  10-20 3320 145 0.95 (0.70; 1.27) 
 
149 0.94 (0.70; 1.26) 
 
70 1.06 (0.70; 1.62) 
  >20 2348 104 0.83 (0.60; 1.16) 
 
121 0.96 (0.69; 1.33) 
 
35 0.79 (0.47; 1.33) 
Histological grade†     
  
  
  
  
 
  Low 899 26 REF (1.00) 
 
26 REF (1.00) 
 
22 REF (1.00) 
  Moderate 2390 111 1.52 (0.98; 2.34) 
 
120 1.65 (1.07; 2.54) 
 
44 0.77 (0.45; 1.29) 
  High 1476 91 1.53 (0.95; 2.47) 
 
98 1.73 (1.08; 2.77) 
 
36 0.77 (0.42; 1.42) 
Lymph nodes     
  
  
  
  
 
   Negative 4702 177 REF (1.00) 
 
183 REF (1.00) 
 
87 REF (1.00) 
   Positive 2750 149 1.30 (1.00; 1.70) 
 
162 1.22 (0.95; 1.59) 
 
54 1.20 (0.79; 1.80) 
ER status     
  
  
  
  
 
  Positive 5952 236 REF (1.00) 
 
276 REF (1.00) 
 
111 REF (1.00) 
  Negative 1271 73 1.33 (0.82; 2.15) 
 
62 0.95 (0.58; 1.57) 
 
28 0.76 (0.37; 1.58) 
Treatment characteristics 
         
Endocrine therapy 
         
 No 1346 75 REF (1.00) 
 
64 REF (1.00) 
 
33 REF (1.00) 
 Yes 6303 252 1.04 (0.65; 1.68) 
 
283 1.22 (0.75; 2.00) 
 
112 0.62 (0.31; 1.23) 
Chemotherapy †     
  
  
  
  
 
  No 4912 158 REF (1.00) 
 
159 REF (1.00) 
 
80 REF (1.00) 
  Yes 2720 167 1.16 (0.86; 1.55) 
 
186 1.36 (1.02; 1.81) 
 
64 0.82 (0.51; 1.29) 
Radiotherapy     
  
  
  
  
 
  No 1810 72 REF (1.00) 
 
81 REF (1.00) 
 
31 REF (1.00) 
  Yes 5839 254 1.11 (0.80; 1.53) 
 
267 1.02 (0.75; 1.38) 
 
114 0.91 (0.55; 1.50) 
Surgery     
  
  
  
  
 
  Partial mastectomy 4627 181 REF (1.00) 
 
188 REF (1.00) 
 
92 REF (1.00) 
  Total mastectomy 3048 147 1.18 (0.89; 1.57) 
 
160 1.13 (0.86; 1.49) 
 
53 0.83 (0.53; 1.31) 
† Hazard ratios are adjusted for all variables listed in the table. The proportional hazards assumption was met for all variables, 
except for comorbidities, histological grade and chemotherapy. Abbreviations: Total No.=the total number of patients; 
No.=the number of observed cases. 
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We analyzed the risk profiles of mental disorders in the Libro-1 cohort and found the risk 
factors for depression and anxiety to be similar. Breast cancer patients at a younger age at 
diagnosis and with comorbid diseases were at increased risk of depression and anxiety. 
Considering the tumor characteristics, we observed an increased risk of depression in patients 
with lymph node-positive disease and increased risk of anxiety in patients with high 
histological grade tumors (Table 6.2). The risk of anxiety was also increased in breast cancer 
patients treated with chemotherapy. However, in general, stress-related disorders were not 
associated with these tumor and treatment factors, except for an increased risk with younger 
age at diagnosis. 
  
Figure 6.3 Time-dependent effect of comorbidity, histological grade and chemotherapy on 
depression and anxiety in the regional breast cancer cohort. 
When testing the proportional hazard assumption for the risk factors, the effect of comorbidity, 
histological grade and chemotherapy was not constant over time. Comorbidity was associated 
with an increased risk of depression and anxiety 3 years after cancer diagnosis, while the effect 
of histological grade and chemotherapy was restricted within the first two years after cancer 
diagnosis (Figure 6.3).  
6.3 PREDICTORS OF PSORIASIS IN BREAST CANCER PATIENTS 
In the nationwide cohort of breast cancer patients, 599 patients were diagnosed with psoriasis, 
corresponding to an incidence rate of 1.9/1000 person-years and a 5-year cumulative incidence 
of 1%. In the matched general population, the incidence rate of psoriasis was 1.7/1000 person-
years, with a 5-year cumulative incidence of 0.8%. Among the patients, the most common 
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psoriasis subtype was psoriasis vulgaris (n=298), followed by palmoplantar pustulosis and 
arthropathic psoriasis.  
 
Figure 6.4 Risk of any psoriasis and psoriasis vulgaris in the nationwide breast cancer cohort 
compared with matched individuals. 
Compared with the matched individuals, breast cancer patients had a 17% increased risk of 
psoriasis (HR=1.17, 95% CI=1.07; 1.28), and this risk increase was mainly caused by psoriasis 
vulgaris, with an HR of 1.33 (95% CI=1.17; 1.52). The risk of psoriasis was highest during the 
second half year after cancer diagnosis, and psoriasis vulgaris has a long-term increased risk 
for up to 12 years. 
Table 6.3 Hazard ratios of psoriasis according to treatment, genetic and lifestyle factors in 
the regional breast cancer cohort.  
 Total No. No. of Cases HR (95% CI) 
Treatment factors    
Endocrine therapy    
    No 1,533 27 1.00 (REF) 
    Yes 7,100 121 0.80 (0.52; 1.24) 
Chemotherapy      
    No 5,544 102 1.00 (REF) 
    Yes 3,070 46 0.70 (0.47; 1.04) 
Radiotherapy     
    No 2,061 23 1.00 (REF) 
    Yes 6,574 125 2.44 (1.44; 4.12) 
Surgery 
  
  
    Lumpectomy 5,203 94 1.00 (REF) 
    Mastectomy 3,459 55 1.54 (1.03; 2.31) 
Genetic and lifestyle factors §    
Polygenic risk score (PRS)    
    Tertile 1 1,440 13 1.00 (REF) 
    Tertile 2 1,442 36 2.83 (1.50; 5.34) 
    Tertile 3  1,483 40 2.98 (1.59; 5.58) 
BMI    
    <25 kg/m2 2,331 40 1.00 (REF) 
    25-30 kg/m2 1,434 28 1.15 (0.71; 1.87) 
    >30 kg/m2 536 19 2.10 (1.20; 3.68) 
Regular smoker (cigarette smoking >1 year)    
    No 1,773 26 1.00 (REF) 
    Yes 2,546 62 1.59 (1.00; 2.52) 
Alcohol consumption    
    No 104 2 1.00 (REF) 
    Yes 2,861 58 1.12 (0.27; 4.70) 
§Analyses were based on a subset of the cohort with information on genetic and lifestyle factors. Abbreviations: CI=Confidence 
interval. Total No.=Number of breast cancer patients. No. of Cases=Number of psoriasis cases. HR=Hazard ratio.  
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In breast cancer patients, radiotherapy was associated with an increased risk of psoriasis after 
adjusting for other treatment factors (HR=2.44, 95% CI=1.44; 4.12). In addition to 
radiotherapy, patients who underwent mastectomy also had an increased risk of psoriasis 
compared with patients with lumpectomy (HR=1.54, 95% CI=1.03; 2.31). Apart from these 
treatment factors, a significant risk increase for psoriasis was also observed in patients with a 
high genetic predisposition to psoriasis (HR=2.94, 95% CI=1.57; 5.49), with regular cigarette 
smoking (HR=1.59, 95% CI=1.00; 2.52), and with a BMI larger than 30 kg/m2 at diagnosis 
(HR=2.10, 95% CI=1.20; 3.68). 
6.4 DISEASE TRAJECTORIES AND MORTALITY IN BREAST CANCER 
PATIENTS 
Among all the diseases in breast cancer patients, we selected 225 diseases with more than 100 
cases after breast cancer diagnosis, and 45 of them had a significantly increased risk after breast 
cancer diagnosis, with number of cases>300, HR>1.5 and p<0.0002 compared with the 
matched controls. Diseases with the highest HRs included lymphedema, radiodermatitis and 
neutropenia, corresponding to the side effects of treatment (Figure 6.5). We also identified 
several side effects of treatment not yet reported, such as the risk of larynx disease (HR=1.86, 
95% CI=1.67; 2.07) and several gynecological disorders. 
 
Figure 6.5 Significant HRs of diseases among breast cancer patients, compared with 
matched individuals 
All risk increases are statistically significant after consideration of the multiple testing issue (p<0.0002). The Y 
axis is in the log scale. The X axis is the disease categories according to ICD codes A-N. Details of the case 
numbers, hazard ratios and confidence intervals are listed in Supplementary Table 1 of Study IV.  
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Compared with the matched controls, breast cancer patients had a 6% increased mortality due 
to other diseases. This increased mortality was mainly contributed by other solid cancers 
(HR=1.16, 95% CI=1.08; 1.24). However, all other causes of mortality were not significant 
after Bonferroni correction. 
We combined the significant diseases in the aforementioned analyses into pairs and tested their 
directionality and strength. Finally, 15 disease pairs passed the tests, with an increased risk of 
D2 after D1 diagnosis (p<0.0013). Many of the disease trajectories were related to the side 
effects of chemotherapy and hormone therapy, such as neutropenia, anxiety, osteoporosis and 
menopausal disorders (Figure 6.6A). These disease pairs were grouped into trajectories for 
breast cancer mortality and other cancer mortality, supported by more than 20 patients in the 
cohort. Breast cancer mortality was associated with the previous diagnosis of neutropenia, 
dorsalgia, and anxiety (Figure 6.6B), while menopausal disorder was a diagnostic indicator for 
other cancers (Figure 6.6C). 
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Figure 6.6 Trajectories of other diseases in breast cancer patients 
The width of the arrows corresponds with the number of disease pairs among breast cancer patients. The color of 
the arrows indicates the OR of the sequential association between the two diseases. The color of the nodes 
represents the HR of this disease among the breast cancer patients, compared to the matched individuals. The 
codes in the nodes are the combined ICD-10 codes for the diseases. 
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7 DISCUSSION 
7.1 METHODOLOGICAL CONSIDERATIONS 
One of the main objectives of an epidemiological study is to discover the effect of exposure on 
outcome occurrence. This approach to measure causal effect usually starts from a valid and 
precise estimation of the statistical association between the exposure and outcome. One major 
goal in achieving this valid association is to avoid systemic error or bias. In addition, chance 
finding and external validity (generalizability) should also be considered. 
7.1.1 Strengths of the studies 
In this thesis, we used the Swedish population and health registers to investigate the 
associations between different diseases and breast cancer, which is the real world evidence of 
disease associations and reflects the clinical practice in Sweden. These registers have a 
nationwide coverage with complete follow-ups and eliminate the related biases for cohort 
studies. The long history of the registers also provide the possibility to study long-term 
associations between diseases and breast cancer. 
Register-based studies are sometimes criticized for less information on covariates. However, 
in our studies, abundant clinical characteristics on tumor and treatment were retrieved through 
linkage to the breast cancer quality register in Study II and III. Lifestyle and genetic information 
is also available in the questionnaires and blood samples in Study III. In addition, in Study I, 
we used the questionnaire-based data and mammograms from KARMA cohort to confirm our 
findings in the registers. 
Another strength of our studies is the statistical methods we used. In study II, we used the 
flexible parametric models to capture the time dependent effect of the exposures. In study IV 
the PheWAS and matched cohort design made it possible to investigate a broad spectrum of 
diseases among breast cancer patients. Furthermore, the disease trajectory analysis allowed us 
to reveal the sequential pattern of disease occurrences and identify key diagnostic indicators 
for poor survival. 
7.1.2 Selection bias 
Selection bias is a systemic error that distorts a valid estimation of the association, in which the 
association in the analyzed population is different from the source population. Selection bias is 
usually introduced during the participant enrollment procedure and follow-up. In the register-
based studies, completeness of the enrollment and follow-up is less of a problem. However, we 
still need to consider the impact of right censoring in the cohorts. 
When studying other diseases in breast cancer patients, right censoring is usually used when 
the patients are dead. However, since breast cancer patients are more likely to die from diseases 
than the controls, this type of censoring is informative when the occurrence of the disease is 
related to censoring (patients cannot develop other diseases after death). Informative censoring 
will result in a shorter follow-up for the breast cancer patients compared with the controls. 
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However, currently, the survival of breast cancer patients is quite good, and thus, this 
informative censoring for mortality would not greatly influence our results. One method to 
address informative censoring is the competing risk model, which allows the follow-up time to 
be continued after a competing event (such as death). In study III, we performed a sensitivity 
analysis using a competing risk model to calculate the cumulative incidence rate. The estimates 
were quite similar to those obtained from the Kaplan-Meier method, confirming that selection 
bias due to informative censoring of death is negligible. 
In the questionnaire-based data analysis in this thesis, we need to consider another type of 
selection bias: survival bias. When we select a subset of the population for study, such as the 
KARMA cohort, we actually selected women who were still alive in 2011. The women who 
died before 2011 were excluded from the cohort, making the KARMA cohort a “healthier” 
population. Since those excluded women likely died from breast cancer, this type of survival 
bias could attenuate the effect of risk factors on breast cancer risk (as the women at highest risk 
were already dead). In Study I, we therefore speculated that survival bias in the KARMA cohort 
would only attenuate the protective effect of preeclampsia and not influence our conclusion. In 
addition to survival bias, the KARMA cohort is actually a collection of health-oriented women 
with a higher level of education and family history, which is supported by a higher incidence 
of breast cancer in the KARMA cohort than in the nationwide cohort. 
7.1.3 Information bias 
Information bias occurs when the measurement or classification of the exposure, outcome or 
covariate is inaccurate. In disease outcome analysis, the main information bias is 
misclassification of the disease outcomes. If the misclassification is non-differential between 
the cases and controls or exposed and un-exposed groups, it will usually attenuate the effect 
and result in a null association. However, if the misclassification is differential between groups, 
it could either overestimate or underestimate the effect. 
In this thesis, we defined other diseases associated with breast cancer by ICD codes, which 
might bias the results if misclassification has occurred. Generally, the validity of ICD codes 
used for disease identification in the Swedish Inpatient Register is approximately 85-95% 
[180], while for specific diseases, the validity for preeclampsia, depression and psoriasis is 
estimated to be 93%, 88% and 81%, respectively [196-199]. Therefore, it is possible that we 
misclassified these diagnoses. For the majority of the outcomes, we believe this 
misclassification in the Patient Register is non-differential between breast cancer patients and 
the healthy population. However, for psoriasis, the possibility of misclassifying it as 
radiodermatitis could be higher in breast cancer patients because radiodermatitis is a known 
side effect of radiotherapy, and the two conditions share several common symptoms in mild 
cases (such as erythema on the skin) [200]. Nevertheless, the severe symptoms of psoriasis are 
quite different from those of radiodermatitis and do not disappear after a couple of weeks. As 
the Patient Register mainly contains severe cases of psoriasis, this potential misclassification 
would not have influenced our results. 
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Another major type of misclassification comes from the medical surveillance of breast cancer 
patients. Because of the increased medical surveillance, as well as the cautiousness from both 
the patients and clinicians, breast cancer patients may receive a diagnosis that in healthy women 
would continue to be undiagnosed. Hence, misclassifying the cases into non-cases would be 
more frequent in the healthy population and consequently reduce the incidence of disease. 
Some observed increased risk of diseases shortly after breast cancer diagnosis could be 
overestimated because of this medical surveillance bias. However, those diseases with a 
considerably high HR or long-term increased risk should not be purely explained by 
surveillance bias. 
For questionnaire-based data, misclassification may also occur when the participants have 
recall bias. When breast cancer patients recall their previous exposure to risk factors, they try 
their best to recall the memory. However, healthy women might not clearly remember the 
exposure, and thus, the exposure is underreported in these women. In the case of the KARMA 
cohort in Study I, preeclampsia history was defined by questionnaires, and breast cancer 
patients are likely to clearly remember their previous diagnosis of preeclampsia. As a result, 
we might underestimate the risk of breast cancer in nonpreeclamptic women. Considering the 
protective effect of preeclampsia on breast cancer risk, this recall bias could only have 
attenuated the association. 
7.1.4 Confounding 
Confounding refers to an association between exposure and outcome caused or influenced by 
a third factor. The confounders should be the risk factors (or ancestor) for both the exposure 
and disease outcome, which are not in the pathway from exposure to outcomes. Confounding 
is an important issue in observational studies when we want to examine the causal effect of 
exposure. Luckily, there are several approaches to exclude the effect of confounders at both the 
study design and statistical analysis stages.  
At the stage of study design, confounders can be controlled by matching, randomization and 
restricting the enrollment criteria. A typical example of matching is the matched cohort design 
used in studies III and IV. In both of the studies, we matched non-cancer individuals to breast 
cancer patients according to age, county of residence and social-economic status. This was 
performed to ensure the distributions of these confounders were the same among the breast 
cancer patients and the controls, thus excluding the potential confounding effect. Another 
benefit of a matched cohort design is that we can use the controls to study many other diseases 
in breast cancer patients, as well as increase the computational efficiency.  
At the stage of statistical analysis, we can use standardization, multivariable regression models 
and stratification to address confounders. In Study II, we used a SIR to control for the 
confounding effect of age, calendar period and residence place when we studied the risk of 
mental disorders in breast cancer patients. In Studies I-III, we always used a multivariable 
model to deal with the effect of potential confounders. For example, in Study I, after adjusting 
for various lifestyle and reproductive risk factors, we still observed a significant association 
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between preeclampsia and breast cancer, suggesting that these potential confounders could not 
explain the observed association. We then hypothesized that inherited factors may contribute 
to this association. When studying the effect of treatment on mental disorders in Study II, tumor 
characteristics were always considered as confounders, since the selection of treatment depends 
on tumor characteristics, while the severity of tumor status may also influence the risk of these 
mental disorders. 
7.1.5 Chance finding and multiple testing 
In hypothesis testing, we usually use the p-value to measure the significance of the association. 
The p-value is the probability that the null hypothesis of no association between the exposure 
and outcome is true. The lower the p-value, the less the probability that we obtain the same 
conclusion according to the null hypothesis of no association. The threshold of the p-value is 
often set at 0.05, allowing a 5% probability of agreement with the null hypothesis, and thus 
rejecting this hypothesis. However, in practice, it is still possible to have a subset of the 
population that incorrectly rejects the true null hypothesis by chance. We acknowledged this 
possibility of chance finding when testing the association between preeclampsia and the PRS 
for breast cancer in Study I since the sample size was limited and the association was weak. 
However, in the nationwide cohort, we found the association between genetic predisposition 
to breast cancer and preeclampsia, and there was a trend of greater risk reduction with a higher 
PRS. Both of these results argued against a chance finding for this association. 
The 5% cut-off for a p-value is also problematic when a large amount of non-hypothesis testing 
has been conducted, simply because the possibility to observe a rare event increases. For 
example, if we perform non-hypothesis testing 100 times, we might find 5 false positive 
significant results just by chance. One method to correct this false positivity is Bonferroni 
correction, which sets the threshold by dividing 0.05 with the number of tested times. In the 
PheWAS analysis in Study IV, we set the threshold for p-value significance by using 
Bonferroni correction and solved the multiple testing problem. 
7.1.6 Generalizability 
In addition to bias, generalizability (also known as the external validity) is also important to 
evaluate the validity of a study. Generalizability evaluates the extent that the conclusion 
generated from one specific study would be true for the entire population or in other situations. 
Some studies may have quite a good design and restrict enrollment criteria, but the conclusion 
can be used only in that specific population (e.g., some clinical trials). In the population-based 
studies in this thesis, studies from Danish and Norwegian populations also reported a similar 
reduced risk of breast cancer in preeclampsia patients [106, 112], as well as a similar level of 
mental disorder risk in breast cancer patients [138, 201], supporting the generalizability of these 
results within Nordic countries. 
However, studies in Asian populations did not find the inverse association between 
preeclampsia and breast cancer [202, 203]. Genetic heterogeneity could be an explanation for 
this difference since we have found that inherited factors contribute to this inverse association. 
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Therefore, caution should be taken in generalizing the findings in this thesis to the Asian and 
African population. 
7.2 INTERPRETATION OF THE RESULTS 
7.2.1 Association between preeclampsia and breast cancer 
In our study, we found an inverse association between preeclampsia and a history of breast 
cancer in a sister, as well as an association between preeclampsia and the PRS for breast cancer, 
suggesting that inherited factors contribute to the inverse association between preeclampsia and 
breast cancer. Both preeclampsia and breast cancer have a heritability of approximately 30% 
[6, 204], and some of the genes related to preeclampsia risk overlap with breast cancer 
susceptibility genes. However, only FLT1 has been validated in a recent GWAS for 
preeclampsia using fetal samples [124]. This is also the reason that we used the PRS for breast 
cancer to predict the risk of preeclampsia in pregnant women and not vice versa. 
In addition to the association between preeclampsia and breast cancer, we also found an inverse 
association between mammographic density, a proxy for breast cancer, and a history of 
preeclampsia in a woman or in her sisters. Therefore, we believe that the inverse association 
between breast cancer and preeclampsia was partly mediated through mammographic density. 
After investigating the genes related to breast cancer risk, higher mammographic density, and 
preeclampsia, we found the risk genes IGF1 to be shared by these three traits. Indeed, a lower 
level of IGF-1 was observed in preeclampsia patients [119], while a higher level of IGF-1 has 
been found in breast cancer patients and women with high mammographic density [120, 121]. 
Further genetic studies for preeclampsia are needed to reveal the exact genetic pathways shared 
by preeclampsia and breast cancer. Understanding the mechanism for this inverse association 
might help to improve the risk prediction for both diseases. 
7.2.2  Time-dependent risk of mental disorders in breast cancer patients 
Our study showed a long-term increased risk of mental disorders in invasive breast cancer 
patients, whereas only a short-term increased risk of stress-related disorders was observed with 
in-situ breast cancer patients. This could be explained by the direct psychological reaction of 
patients to the diagnosis of cancer. In-situ cancer is usually considered a less life-threatening 
disease, and patients are treated with surgery and radiotherapy, without suffering from the 
severe side effects of chemotherapy and endocrine therapy. Therefore, in-situ cancer patients 
generally have a less severe psychosocial reaction. 
We found and confirmed several risk factors for depression and anxiety in breast cancer 
patients, such as younger age at diagnosis, comorbid disease, high tumor grade and 
chemotherapy. Breast cancer patients diagnosed at a younger age might be influenced by the 
change in work ability, sexual life, motherhood and fertility [130, 205-208], which are less of 
a concern in older patients. In addition, breast cancer patients with other comorbid diseases 
have an additional risk for mortality [101, 209]. These patients might worry more about their 
future survival and consequently develop mental disorders. 
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The effect of tumor grade and chemotherapy on depression and anxiety risk was limited to 
within two years after cancer diagnosis. Patients diagnosed with a high-grade tumor might 
consider it a more severe disease, and experience a stronger psychological reaction. 
Chemotherapy is associated with several side effects, such as alopecia, nausea and vomiting 
[142, 143], which may further increase the risk of depression and anxiety. Therefore, the effect 
of tumor grade and chemotherapy is expected to diminish once the diagnosis is set and the 
treatment is completed. 
7.2.3 Predictors of psoriasis in breast cancer patients 
The psychological reaction to the cancer diagnosis can not only increase the risk of mental 
disorders in breast cancer patients but can also increase the risk of certain somatic symptoms, 
such as psoriasis. Severe stressful life events have been shown to increase the risk of psoriasis 
[152], and in our study, we found a slightly increased risk of psoriasis among breast cancer 
patients. The increased risk of psoriasis was mainly present during the first year after cancer 
diagnosis, confirming its association with the diagnosis event or treatment decision. 
Another plausible explanation for the risk of psoriasis was the dermatological side effects of 
breast cancer treatment. Skin trauma is one of the major triggers for psoriasis onset [150]. We 
found a significantly increased risk of psoriasis in breast cancer patients treated with 
radiotherapy, suggesting ionized radiation as a cause of skin trauma to trigger psoriasis. We 
also identified that patients treated with mastectomy had an increased risk of psoriasis. Since 
patients that underwent a mastectomy usually have delayed wound healing [210] and an 
abnormal wound healing process is involved in the pathogenesis of psoriasis [151], we believe 
prolonged wound healing could partly explain this increased risk of psoriasis. 
7.2.4 Disease trajectories and mortality in breast cancer patients 
Many of the diseases with an increased risk after breast cancer diagnosis were associated with 
treatment side effects. For example, diseases with the highest HRs in the breast cancer patients 
included lymphedema, radiodermatitis and neutropenia, which are known side effects of 
surgery, radiotherapy and chemotherapy [75, 83, 211]. In addition, we also identified several 
diseases that had not been previously reported in breast cancer patients, such as larynx diseases 
and several gynecological disorders. Since larynx diseases are associated with exogenous 
hormones (e.g., oral contraceptives) [212], this increased risk of larynx diseases might be the 
side effect of hormonal therapy. 
Among all the other diseases with an increased risk after breast cancer diagnosis, other cancers 
were the only cause of mortality with an increased mortality rate compared with the matched 
controls. In the further trajectory analysis for diseases leading to other cancer mortality, we 
found the increased incidence of menopausal disorders to be associated with the risk of other 
cancers. Menopausal disorder is a common side effect of hormonal therapy. One important 
symptom of menopausal disorder, uterine bleeding, is a known predictor of endometrial cancer 
[213]. Since tamoxifen increases the risk of endometrial cancer [50], a genital tract examination 
should be recommended during the follow-ups for patients treated with tamoxifen. 
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In the disease trajectories leading to breast cancer mortality, we found the diagnosis of 
neutropenia, dorsalgia and anxiety to be associated with breast cancer mortality. Since 
neutropenia is a side effect of chemotherapy and chemotherapy is usually given to patients with 
advanced tumors, it is reasonable that neutropenia is associated with breast cancer mortality. 
Dorsalgia has long been considered a sign of bone metastasis [214], while the risk of anxiety 
is increased after chemotherapy and associated with advanced tumor characteristics [215]. 
Indeed, all these three diseases are signs of aggressive tumor characteristics in breast cancer 
and consequently associated with a worse prognosis. Our findings further suggest that 
clinicians (especially general practitioners) and patients should pay special attention to 
dorsalgia symptoms, considering its association with bone metastasis. 
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8 CONCLUSION 
In this thesis, we provided a broad picture of diseases associated with breast cancer. We 
selected preeclampsia before breast cancer diagnosis to test the inverse association between 
these two hormone-related diseases and to examine inherited factors contributing to this 
association. We also studied the risk of mental disorders and psoriasis after breast cancer 
diagnosis, with a focus on the treatment characteristics predicting risk of these diseases. Finally, 
in the attempt to describe a wide spectrum of diseases after breast cancer diagnosis, we detected 
some sequential associations between the incidence and mortality of different diseases. After 
the aforementioned studies, a few conclusions might be noted:  
 Women with a disease history of preeclampsia have a lower risk of breast cancer and a 
lower mammographic density. This inverse association between preeclampsia and 
breast cancer can be partly explained by the shared genetic variants and suggests history 
of preeclampsia to be involved in the assessment for breast cancer risk. 
 
 Invasive breast cancer diagnosis is a stressful life event and consequently influences 
both mental and somatic health, such as the increased risk of depression, anxiety, and 
psoriasis. In-situ cancer diagnosis is a less severe life event and only increases risk of 
stress-related disorders in a short-term. 
 
 Younger age at cancer diagnosis, tumor grade, chemotherapy and comorbidity are 
independent risk factors for depression and anxiety in breast cancer patients, with tumor 
grade and chemotherapy conferring to short term risk increase, while comorbidity for 
long term risk increase.  
 
 Many of the diseases with an increased risk after breast cancer diangosis are associated 
with treatments for breast cancer. For example, the risk of depression and anxiety is 
increased after chemotherapy, and radiotherapy and mastectomy may influence 
patients’ risk of psoriasis. A multidisciplinary post cancer care is therefore needed to 
deal with these side effects of treatments.  
 
 Despite the increased risk of many non-communicable diseases, other solid cancer is 
the only disease with a more lethal feature when diagnosed in breast cancer patients as 
compared to the general population, and its risk could be predicted by the occurrence 
of menopausal disorders. We therefore recommend closer surveillance for other solid 
cancer in breast cancer patients. 
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9 FUTURE PERSPECTIVES 
As majority of the breast cancer cases are hormone related, many studies have already tested 
several diseases to be predictors of breast cancer incidence, such as benign breast disorders and 
preeclampsia. Although our study and some other studies have confirmed the inverse 
association between breast cancer and preeclampsia, and genetic variants may contribute to 
this inverse association, the exact genetic variants shared by both diseases are still unknown. 
Therefore, large scale GWAS for preeclampsia is needed to reveal the genetic background of 
preeclampsia and to combine with the GWAS results from breast cancer studies to identify the 
pleiotropic genes.  
In addition, current studies usually hypothesized hormone-related diseases and autoimmune 
diseases to be associated with breast cancer risk. However, some other diseases might also 
predict breast cancer risk. For this reason, a hypothesis generating study is needed to screen 
across all the diseases before breast cancer diagnosis to identify new indicators. Considering 
the heterogeneity among different molecular subtypes of breast cancer, the associations 
between diseases and breast cancer risk might be different according to subtypes, which needs 
further tests. 
Previously, several interventions were reported to be effective in controlling short-term 
depression and anxiety among cancer patients [216]. Considering that the highest risk of mental 
disorders occurs in the first year after breast cancer diagnosis, as well as the limited effect of 
tumor characteristics and chemotherapy within two years, these interventions are strongly 
recommended for younger patients with advanced tumor characteristics scheduled for 
chemotherapy. Future clinical trials could be initiated to evaluate these psychosocial and 
pharmacologic interventions in this targeted group of breast cancer patients. 
We found genetic predisposition to psoriasis can predict the risk of psoriasis in breast cancer 
patients. Together with evidence on the genetic prediction of other diseases in breast cancer 
patients [217], we believe that the PRS could be used to predict side effects of treatment with 
an inheritable feature. In order to validate the role of PRS in treatment side effects prediction, 
we should first of all find out those side effects (or diseases) strongly influenced by family 
history, and with known GWAS results. A further attempt could be to develop a package of 
SNPs (in combination with other biomarkers) as a toolkit to predict all the severe side effects 
of breast cancer treatments and provide clinical awareness for treatment decision. 
We have identified several communicable and non-communicable diseases with an increased 
risk after breast cancer diagnosis. Since many of the diseases are related to cancer treatment 
and treatment patterns may vary in different health care settings, replication of our results in 
US and Asian populations is needed before initiating interventions for these diseases. In 
addition, validation of the disease trajectories after breast cancer diagnosis should be performed 
outside the Nordic countries. 
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The improvement of cancer treatments has already turned breast cancer from a fatal disease to 
a chronic disease, which is frequently comorbid with other disorders. Therefore, long term 
survival of the breast cancer patients might also be influenced by comorbidities.  Nevertheless, 
the current prognostic prediction models mainly focus on five or ten years survival and depend 
on only tumor characteristics [218]. Development and validation of a new comorbidity index 
focusing on long-term survival in breast cancer patients are needed to subdivide the patients 
and provide personalized follow-ups and interventions accordingly. 
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